North West England MRC Fellowships in Clinical Pharmacology and Therapeutics

Lead Research Organisation: University of Liverpool
Department Name: Biomedical Sciences

Abstract

In a recent report from the Office for Life Sciences, Clinical Pharmacology was highlighted as
a specialty vital for healthcare and industry in the UK. Our proposed scheme builds upon a
highly successful training programme in Clinical Pharmacology, based at the University of
Liverpool. Our unique selling point is the collaboration between the Universities of Liverpool
and Manchester based on the existing MRC Centre for Drug Safety Science, and with 2
pharmaceutical companies (AstraZeneca and GlaxoSmithKline) and 2 contract research
organisations (ICON and Medicines Evaluation Unit). We focus on important subject areas,
including paediatrics, where there is a fundamental need to improve drugs for children. The
scheme is designed to identify the best students, provide them with ?without walls? training
through attachments with our industry partners, together with excellent supervision and
mentoring arrangements, all of which enhance the student learning experience. Over 4
years, we will train 12 clinical fellows to undertake PhDs; each project will be tailored to the
individual and their clinical training. The Clinical Pharmacology skills base in the UK will be
enhanced by the scheme with benefit to healthcare, academia, industry, regulation and
ultimately undergraduate training.

Technical Summary

The North West Clinical Pharmacology Training programme utilises the complementary
expertise of:
the Universities of Liverpool and Manchester building upon strengths in translational
research and;
Two major pharmaceutical companies (AstraZeneca and GlaxoSmithKline) and 2
contract research organisations (ICON and Medicines Evaluation Unit) to provide a
highly integrated !?without walls!? training scheme.
The programme is based on an established Liverpool-Manchester collaboration, the MRC
Centre for Drug Safety Science, which provides the management framework. It is based
around the successful training programme which has been the hallmark of the Department of
Pharmacology and Therapeutics in Liverpool, where there is a seamless working relationship
between clinical and basic pharmacologists. The focus of the scheme will be on Stratified
Medicines and Drug Safety in the clinical areas of Paediatrics, Infectious Diseases and
Inflammation and Repair. Over a period of 4 years, we aim to train 12 clinical research
training fellows to undertake a doctoral thesis. The fellows. specific skills training will be
supplemented with generic and transferable skills training. We will implement a taught clinical
pharmacology programme in keeping with the curriculum approved by JRCPTB. Trainees will
interact closely with our industrial partners. Industrial placements will be developed in a
bespoke manner to suit the individual needs of the trainee and their project aims. The key to
the programme is its flexibility which will enhance the student experience. A two-stage
interview procedure will be implemented to ensure the selection of the best students and the
best projects consistent with the recruitment procedures utilised with the MRC. Academic
clinical fellows will form the main source for recruits. All trainees will be comprehensively
monitored, being supported by their supervisors, an advisory panel and mentor. Annual
showcase events will allow fellows to present their work, and interact with other students,
and key players from both Universities and external academics. We envisage, and will
actively promote, that on completion of the PhD, the trainees will move to lecturer posts. Our
partners have contributed 46% of the total cost of the programme which represents
significant added value. Our aim is to develop high-calibre clinician scientists of the future
with the ability to link bi-directionally between clinical and basic science, from molecule to
man, and from bench to bedside. Such individuals will have benefited from research
experience in the settings of academia and industry, and could thus function as future
research leaders in either sector.

Organisations

Publications

10 25 50

publication icon
Bluett J (2013) Cervical spine calcinosis in systemic sclerosis. in The Journal of rheumatology

 
Description Acting as Early Academic Career Representative on Careers Committee (Amy Foulkes)
Geographic Reach Local/Municipal/Regional 
Policy Influence Type Membership of a guideline committee
 
Description Amy Foulkes: Invitation to attend Academy of Medical Sciences 'Shape of Training' review as registrar representative. Meeting to take place on 6th Dec London at AMS
Geographic Reach National 
Policy Influence Type Participation in a national consultation
 
Description Arthritis Research UK Inflammatory Arthritis, Clinical Study Group, Steering Group member, Trainee representative (Meghna Jani)
Geographic Reach National 
Policy Influence Type Participation in a advisory committee
Impact Aim of the ARUK CSG is to develop a national funding strategy for the charity in the field of inflammatory arthritis. Selection into the CSG is a national competitive process
 
Description Elected Member of the Trainees and Members Committee at the Royal College of Physicians in Edinburgh (Dr Anna Olsson-Brown)
Geographic Reach National 
Policy Influence Type Influenced training of practitioners or researchers
Impact The committee has three main foci - Representation at National level pertaining to post-graduate training and representation; Education resulting in the composition and delivery of national lecture series "Evening Medical Updates" and a yearly symposium "Medical Trainees Conference" and Careers and Communication which is focused on the development and support of post graduate training within the medical specialties.
 
Description Ensuring UK leadership in experimental medicine
Geographic Reach National 
Policy Influence Type Implementation circular/rapid advice/letter to e.g. Ministry of Health
URL https://www.bps.ac.uk/BPSMemberPortal/media/BPSWebsite/Assets/Ensuring-UK-leadership-in-experimental...
 
Description Lead SpR and co-authored the Greater Manchester Medicines Management Group (GMMMG) /MAHSC guidelines on biologic use in rheumatoid arthritis (Meghna Jani)
Geographic Reach Local/Municipal/Regional 
Policy Influence Type Participation in advisory committee
Impact -Participation in advisory committee and presentation of guidelines to GMMMG on behalf of the steering group -The aim is to standardise prescribing practices and safety checklists of biologic treatment. - This has allowed clinicians to use biologics outside of NICE guidelines for indications that there is scientific evidence in. It also aids recruitment to CLRN studies and clinical trials. - Updated and revised for use in September 2014. To be uploaded on NICE website, as evidence of good local practice
 
Description Member of LHP Oncology Education Group (Dr Anna Olsson-Brown)
Geographic Reach Local/Municipal/Regional 
Policy Influence Type Membership of a guideline committee
Impact This group has contributed to a number of training days (Regional and National) and supports an Acute Oncology Master level module at the University of Liverpool. The next educational session pertains to Oncology and Genomics.
 
Description Member of UKONS Oncology Working Group (Dr Anna Olsson-Brown)
Geographic Reach National 
Policy Influence Type Membership of a guideline committee
 
Description Member of the EULAR task force for the management of Rheumatoid Arthritis
Geographic Reach Multiple continents/international 
Policy Influence Type Participation in a advisory committee
Impact To influence international guidelines for management of rheumatoid arthritis
 
Description National Prescribing Safety Assessment (Lauren Walker)
Geographic Reach National 
Policy Influence Type Participation in a advisory committee
Impact Lauren Walker is currently the specialty trainee representative for the British Pharmacological Society (BPS) on both the clinical section committee and the education and training committee. Through the latter, she has been involved in the introduction of learning resources to compliment the National Prescribing Safety Assessment aimed at improving the prescribing skills of junior doctors. This has involved writing interactive electronic presentations for the online e-Learning in Clinical Pharmacology/Prescribing - www.prescribe.ac.uk.
 
Description NeuroAccess. A project to improve clinical neurology and the outcome of neurological infections through training links with sub-Saharan Africa (Sam Nightingale)
Geographic Reach Africa 
Policy Influence Type Influenced training of practitioners or researchers
Impact The impact has not been formally measured, but the aim is to improve the outcome of patients with neurological illness in particular that related to neurological infection, through forming on-going connections with hospitals in sub-Saharan Africa.
URL http://www.neuroaccess.org
 
Description NeuroID eLearning: an open access online resource for clinical information on neurological infection (Sam Nightingale)
Geographic Reach Multiple continents/international 
Policy Influence Type Influenced training of practitioners or researchers
Impact To date over 1000 people from 5 continents have accessed the site.
URL http://www.braininfectionsuk.org/neuroid_elearning/index.html
 
Description Prevent Atrial Fibrillation Stroke: Tackling Challenges and Accelerating Improvements (Vincent Yip)
Geographic Reach Local/Municipal/Regional 
Policy Influence Type Participation in a advisory committee
 
Description Royal College of Physicians Careers Fayre London October 2013 (Lauren Walker)
Geographic Reach National 
Policy Influence Type Influenced training of practitioners or researchers
 
Description Use of cystatin C as biomarker for acute kidney injury at Royal Manchester Children's Hospital
Geographic Reach Local/Municipal/Regional 
Policy Influence Type Influenced training of practitioners or researchers
URL http://www.cmft.nhs.uk/15405.aspx
 
Description Award for methotrexate assay development (James Bluett)
Amount £10,000 (GBP)
Organisation National Institute for Health Research 
Department NIHR Manchester Musculoskeletal Biomedical Research Unit
Sector Public
Country United Kingdom of Great Britain & Northern Ireland (UK)
Start 06/2014 
End 02/2016
 
Description BHIVA Research Award (Awarded to Sam Nightingale)
Amount £9,810 (GBP)
Organisation British HIV Association (BHIVA) 
Sector Charity/Non Profit
Country United Kingdom of Great Britain & Northern Ireland (UK)
Start 10/2011 
End 10/2013
 
Description Bursary to attend IQ course (awarded to Amy Foulkes)
Amount £99 (GBP)
Organisation Pfizer Ltd 
Sector Private
Country United Kingdom of Great Britain & Northern Ireland (UK)
Start 10/2012 
End 10/2012
 
Description Bursery to attend British Association of Dermatologists Conference (Awarded to Amy Foulkes)
Amount £228 (GBP)
Organisation Abbott 
Department Abbott UK
Sector Private
Country United Kingdom of Great Britain & Northern Ireland (UK)
Start 07/2013 
End 07/2013
 
Description Conference attendance award - International Investigative Dermatology Meeting Edinburgh 2013 (Amy Foulkes)
Amount £1,000 (GBP)
Organisation AbbVie 
Sector Private
Country Global
Start 05/2013 
End 05/2013
 
Description Conference attendance award from Pfizer Ltd. - Gene to Clinic - 6th International Congress in Psoriasis (Awarded to Amy Foulkes)
Amount £400 (GBP)
Organisation Pfizer Ltd 
Sector Private
Country United Kingdom of Great Britain & Northern Ireland (UK)
Start 12/2011 
End 12/2011
 
Description Direct application to the Encephalitis society (Sam Nightingale)
Amount £1,074 (GBP)
Organisation The Encephalitis Society 
Sector Charity/Non Profit
Country United Kingdom of Great Britain & Northern Ireland (UK)
Start 05/2012 
End 12/2013
 
Description EULAR Young Investigator Travel Bursary (Sarah Skeoch)
Amount € 350 (EUR)
Organisation The European League Against Rheumatism (EULAR) 
Sector Charity/Non Profit
Country Switzerland, Swiss Confederation
Start 06/2012 
End 06/2012
 
Description EULAR travel bursary (2) (Meghna Jani)
Amount £1,200 (GBP)
Organisation The European League Against Rheumatism (EULAR) 
Sector Charity/Non Profit
Country Switzerland, Swiss Confederation
Start 06/2014 
End 06/2014
 
Description EULAR travel bursary (Meghna Jani)
Amount £1,200 (GBP)
Organisation The European League Against Rheumatism (EULAR) 
Sector Charity/Non Profit
Country Switzerland, Swiss Confederation
Start 06/2013 
End 06/2013
 
Description European Cystic Fibrosis Society Travel Grant (Stephen McWilliam)
Amount € 300 (EUR)
Organisation European Cystic Fibrosis Society (ECFS) 
Sector Charity/Non Profit
Country European Union (EU)
Start 06/2014 
End 06/2014
 
Description European Society of Clinical Microbiology and Infectious Diseases travel award (awarded to Tim Felton)
Amount € 500 (EUR)
Organisation European Society of Clinical Microbiology and Infectious Diseases (ESCMID) 
Sector Learned Society
Country European Union (EU)
Start 04/2012 
End 04/2012
 
Description Genetic Predisposition to clozapine agranulocytosis
Amount £10,000 (GBP)
Organisation Mersey Care NHS Trust 
Sector Public
Country United Kingdom of Great Britain & Northern Ireland (UK)
Start 04/2013 
End 04/2017
 
Description Health Technology Assessment (Tim Felton)
Amount £1,600,000 (GBP)
Organisation National Institute for Health Research 
Sector Public
Country United Kingdom of Great Britain & Northern Ireland (UK)
Start  
 
Description Invention for Innovation (Tim Felton)
Amount £427,611 (GBP)
Organisation National Institute for Health Research 
Sector Public
Country United Kingdom of Great Britain & Northern Ireland (UK)
Start  
 
Description Lupus Academy Travel Award (awarded to John Reynolds)
Amount £750 (GBP)
Organisation St. Thomas' Lupus Trust 
Department Lupus Academy
Sector Academic/University
Country United Kingdom of Great Britain & Northern Ireland (UK)
Start 04/2013 
End 04/2013
 
Description MRC Centenary Early Career Award (Sam Nightingale)
Amount £35,662 (GBP)
Organisation University of Liverpool 
Department MRC Centre for Drug Safety Science
Sector Public
Country United Kingdom of Great Britain & Northern Ireland (UK)
Start 04/2013 
End 01/2014
 
Description Manchester Biomedical Research Unit grant (Meghna Jani)
Amount £9,000 (GBP)
Organisation National Institute for Health Research 
Department NIHR Manchester Musculoskeletal Biomedical Research Unit
Sector Public
Country United Kingdom of Great Britain & Northern Ireland (UK)
Start 04/2015 
End 04/2016
 
Description Medical Research Council Confidence in Concept Scheme (Sarah Skeoch)
Amount £55,035 (GBP)
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom of Great Britain & Northern Ireland (UK)
Start 07/2015 
End 02/2017
 
Description NIHR Manchester Musculoskeletal Biomedical Research Unit Pump Priming grant (Sarah Skeoch)
Amount £15,000 (GBP)
Organisation National Institute for Health Research 
Department NIHR Manchester Musculoskeletal Biomedical Research Unit
Sector Public
Country United Kingdom of Great Britain & Northern Ireland (UK)
Start 09/2014 
End 03/2016
 
Description North West England MRC FELLOWSHIPS in Clinical Pharmacology and Therapeutics
Amount £3,052,098 (GBP)
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom of Great Britain & Northern Ireland (UK)
Start 10/2016 
End 10/2021
 
Description PROteKT study grant award (Stephen McWilliam)
Amount £258,075 (GBP)
Organisation J P Moulton Charitable Foundation 
Sector Charity/Non Profit
Country United Kingdom of Great Britain & Northern Ireland (UK)
Start 06/2014 
End 09/2017
 
Description Proximity to Discovery award (Amy Foulkes)
Amount £24,593 (GBP)
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom of Great Britain & Northern Ireland (UK)
Start 09/2016 
End 09/2017
 
Description Proximity to Discovery award - in kind contribution (Amy Foulkes)
Amount £52,940 (GBP)
Organisation Novartis 
Sector Private
Country Global
Start 09/2016 
End 09/2017
 
Description Research for Patient Benefit (Tim Felton)
Amount £348,344 (GBP)
Organisation National Institute for Health Research 
Sector Public
Country United Kingdom of Great Britain & Northern Ireland (UK)
Start  
 
Description Starter Grant for Clinical Lecturers (Amy Foulkes)
Amount £30,000 (GBP)
Organisation Academy of Medical Sciences (AMS) 
Sector Charity/Non Profit
Country United Kingdom of Great Britain & Northern Ireland (UK)
Start 02/2017 
 
Description The University of Liverpool Confidence in Concept Scheme (Lauren Walker)
Amount £9,504 (GBP)
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom of Great Britain & Northern Ireland (UK)
Start 07/2015 
End 07/2016
 
Description Trainee of the Year Third Prize (Amy Foulkes)
Amount £500 (GBP)
Organisation Royal Society of Medicine 
Sector Learned Society
Country United Kingdom of Great Britain & Northern Ireland (UK)
Start  
 
Description Travel award from Astellas Pharma (Awarded to Tim Felton)
Amount £1,250 (GBP)
Organisation Astellas Pharma 
Sector Private
Country Japan
Start  
 
Description University of Liverpool internal Institute of Global Health pump priming award to set up NeuroID eLearning (Sam Nightingale)
Amount £550 (GBP)
Organisation University of Liverpool 
Sector Academic/University
Country United Kingdom of Great Britain & Northern Ireland (UK)
Start 05/2011 
End 05/2012
 
Title Bank of Biological Samples used by PSORT (Amy Foulkes) 
Description Bank of biological samples (human blood, tissue and urine) with associated clinical database. 
Type Of Material Biological samples 
Year Produced 2013 
Provided To Others? Yes  
Impact This collection, the main part of Amy Foulkes Fellowship project, has now been taken on as pilot data for the Psoriasis Stratification of Optimised Treatment Responses PSORT pilot data, granted a £7.2 million bid for a larger clinical study over following years. 
 
Title Combined cardiovascular drug quantification method (Richard Myles Turner) 
Description Dr Richard Turner has worked alongside a post-doctoral colleague to develop a novel liquid-chromatography mass spectrometry assay that can simultaneously quantify the steady-state levels of atorvastatin, three major atorvastatin metabolites, bisoprolol and clopidogrel carboxylic acid from patient plasma samples. The assay has been developed, validated, and used to determine the plasma concentrations of these analytes in over 1,000 patients. 
Type Of Material Technology assay or reagent 
Provided To Others? No  
Impact The analysis of patient samples has been conducted; statistical analysis is on-going. 
 
Title Dried blood spot statin quantification assay (Richard Myles Turner) 
Description Richard Turner has worked alongside a bioanalytical chemist to develop a novel liquid-chromatography mass spectrometry assay that can quantify rosuvastatin and atorvastatin levels from dried blood spot samples. It has been developed for use with murine samples and so will contribute to reducing the numbers of mice involved in murine statin pharmacokinetic studies, and will be validated for use with human samples A murine pharmacokinetic study has been undertaken, and its results will be presented at the British Pharmacology Society Annual Winter meeting, 2016. 
Type Of Material Technology assay or reagent 
Provided To Others? No  
Impact A pharmacokinetic study is planned 
 
Title Drug mass spect assays (Sam Nightingale) 
Description Fellow: Sam Nightingale has developed 11 drug mass spect assay to measure CSF levels of antiretrovirals. 
Type Of Material Cell line 
Provided To Others? No  
Impact None yet. 
 
Title Measurement of MTX and 7-OH-MTX using HPLC-SRM-MS (James Bluett) 
Description Measurement of MTX and 7-OH-MTX using HPLC-SRM-MS 
Type Of Material Technology assay or reagent 
Provided To Others? No  
Impact Published a paper describing the method to measure MTX and 7-OH-MTX using HPLC-SRM-MS 
 
Title Mouse model development (James McCaffrey) 
Description James McCaffrey is creating podocyte specific transgenic knock-out of glucocorticoid receptor in mice 
Type Of Material Model of mechanisms or symptoms - mammalian in vivo 
Provided To Others? No  
Impact Model being developed within lab 
 
Title Online case record form (Sam Nightingale) 
Description Fellow:Sam Nightingale has developed an online case record form to allow secure data input from multiple sites. 
Type Of Material Biological samples 
Provided To Others? No  
Impact None yet. 
 
Title Database- chromatin immunoprecipitation sequencing (ChIP-Seq) (James McCaffrey) 
Description Database- chromatin immunoprecipitation sequencing (ChIP-Seq) for glucocorticoid receptor in kidney cell line. 
Type Of Material Database/Collection of data 
Provided To Others? No  
Impact None yet. This dataset is likely to be made publicly available 
 
Title Database- whole genome microarray (James McCaffrey) 
Description Database- chromatin immunoprecipitation sequencing (ChIP-Seq) for glucocorticoid receptor in kidney cell line. 
Type Of Material Database/Collection of data 
Provided To Others? No  
Impact Not yet 
 
Title Pharmacogenetics of acute coronary syndrome database (Richard Myles Turner) 
Description This database is derived from a recently completed prospective cohort study that recruited 1470 patients hospitalised with a non-ST elevation acute coronary syndrome in the UK. Clinical, demographic and biological samples were collected. I was involved in systematically and rigorously querying the data to ensure it is accurate and as complete as possible, validating the clinical endpoints, and performing statistical analysis with the clinical data. 
Type Of Material Database/Collection of data 
Year Produced 2015 
Provided To Others? Yes  
Impact The research team have provided a focussed part of the database to another research group. Thus far, an oral presentation of the clinical data analysis won a conference communications prize. i) Publication of an analysis of clinical data within this dataset pertaining to suboptimal statin utilisation (see section 1) ii) An oral presentation that I gave of the above clinical data analysis won a conference communications prize (see section 14).# 
URL http://www.sciencedirect.com/science/article/pii/S1933287416304548
 
Title Whole cell proteomic analysis of kidney cell line and discovery of Gc-regulated proteins (James McCaffrey) 
Description Mass spectrometry data on protein constituents of kidney cells and identification of glucocorticoid-regulated proteins 
Type Of Material Database/Collection of data 
Provided To Others? No  
Impact None yet 
 
Description 24hr biomarker profile in healthy volunteers (Lauren Walker) 
Organisation ICON
Department Clinical Pharmacology Unit
Country United States of America 
Sector Private 
PI Contribution Lauren Walker designed the study in collaboration with ICON, she designed the protocol, patient leaflet and consent forms etc. together with support from ICON particularly the medical director and she did the ethics application and attended the meeting with the medical director.
Collaborator Contribution ICON (USA Site) undertook the screening, recruitment and inpatient stay, including collection of the samples, for which they covered all of the costs.
Impact Samples analysed for circadian variability, combined with a panel of other liver-related biomarkers, results incorporated into a scientific paper (in preparation).
Start Year 2011
 
Description AED development programme (Lauren Walker) 
Organisation University of Utah
Department Preclinical Research Resource (PRR)
Country United States of America 
Sector Academic/University 
PI Contribution Lauren Walker designed the sample collection time frame. Samples were analyzed at the university of Liverpool.
Collaborator Contribution The AED DDP screen all new anti-convulsants through an established maximum electro-shock mouse model of seizures. They collected serum and brain samples at time points following seizure. They met the cost of the rodents.
Impact The samples have been analysed and this will be incorporated into a scientific paper (in preparation).
Start Year 2012
 
Description AZ-UOM Strategic Alliance Fund (Sarah Skeoch) 
Organisation AstraZeneca
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Private 
PI Contribution Sarah Skeoch and her research team have included members of Astra Zeneca in discussions of study set up and will report our findings in the 1st 12 patients involved in the study to the alliance.
Collaborator Contribution Sarah Skeoch and her research team applied for funding to the alliance and were granted funding for equipment, training and imaging costs.
Impact Abstracts published
Start Year 2011
 
Description Arthritis Research UK EU (Sarah Skeoch) 
Organisation Arthritis Research UK
Department Arthritis Research UK Epidemiology Unit
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Academic/University 
PI Contribution Sarah Skeoch is based within this unit where she participates in teaching and research activities.
Collaborator Contribution Sarah Skeoch is based within this unit where she participates in teaching and research activities. She is provided with teaching, pastoral and IT support and desk space.
Impact Abstract at EULAR 2012 Conference
Start Year 2012
 
Description Biomarker-guided duration of antibiotic treatment Group (Tim Felton) 
Organisation Intensive Care Society
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Learned Society 
PI Contribution Tim Felton has been Invited to join collaborative group studying the use of biomarkers to guide duration of antibiotics. Clinicians and clinical trialist from across the UK involved with the support of the Intensive Care Society. Has led to successful submission of an NIHR Health Technology Appraisal grant "Biomarker-guided duration of antibiotic treatment". The proposed trial will be a three-arm randomised control trial of 2760 patients. (£1,590629).
Collaborator Contribution Tim Felton has been Invited to join collaborative group studying the use of biomarkers to guide duration of antibiotics. Clinicians and clinical trialist from across the UK involved with the support of the Intensive Care Society. This has led to submission of an NIHR Health Technology Appraisal grant "Biomarker-guided duration of antibiotic treatment". The proposed trial is a three-arm randomised control trial of 2760 patients. (£1,590629).
Impact Application to NIHR for a Health Technology Appraisal Grant of £1,590,629
Start Year 2015
 
Description Biomarkers in brain and blood Study (Lauren Walker) 
Organisation The Walton Centre NHS Foundation Trust
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Public 
PI Contribution Lauren Walker designed the study, put together the protocol, patient leaflet and consent forms etc and did the ethics application and attended the meeting. Lauren Walker collected all the CSF and serum samples and recruited all the patients
Collaborator Contribution Active support from the centre in patient recruitment
Impact The samples have been analysed and will be compared to a second set of collected samples (yet to be analysed) and this will be incorporated into a scientific paper.
Start Year 2012
 
Description Birmingham Heartlands Hospital (Sam Nightingale) 
Organisation Birmingham Heartlands Hospital
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Hospitals 
PI Contribution Participants in a multi site study lead by Dr Sam Nightingale (Clinical Fellow) who has attended for Site Initiation Visit and provides ongoing support to the clinical team : A) CNS Penetration of Antiretrovirals B) The CNS as a sanctuary site for HIV
Collaborator Contribution 19 patients were recruited to Study A of PARTITION and 5 patients were recruited to study B of PARTITION.
Impact 19 patients were recruited to Study A of PARTITION and 5 patients were recruited to study B of PARTITION. Analysis of samples is ongoing.
Start Year 2012
 
Description Bonventre Lab Collaboration (Stephen McWilliam) 
Organisation Brigham and Women's Hospital
Country United States of America 
Sector Hospitals 
PI Contribution Stephen McWilliam and his research team have provided the collaborator with samples for analysis from studies they are conducting
Collaborator Contribution The collaborators have contributed through sample analysis and co-authoring a research paper and abstracts
Impact - McWilliam SJ, Antoine DJ, Sabbisetti V, Pearce RE, Jorgensen AL, Lin Y, Leeder JS, Bonventre JV, Smyth RL, Pirmohamed M. Reference intervals for urinary renal injury biomarkers KIM-1 and NGAL in healthy children. Biomark Med. 2014, 8(10):1189-1197 - McWilliam SJ, Antoine DJ, Sabbisetti V, Turner MA, Farragher T, Bonventre JV, Park BK, Smyth RL, Pirmohamed M. Mechanism-Based Urinary Biomarkers to Identify the Potential for Aminoglycoside-Induced Nephrotoxicity in Premature Neonates: A Proof-of-Concept Study. PLoS ONE 7(8): e43809, 2012. doi:10.1371/journal.pone.0043809 PMID: 22937100 -D.J. Antoine, S. McWilliam, V. Sabbisetti, M. Turner, R. Smyth, M. Pirmohamed, J.V. Bonventre, B.K. Park. Measurement of the urinary biomarker KIM-1 identifies the potential for aminoglycoside-induced nephrotoxicity in premature neonates. Toxicology 290(2-3):107, 2011. doi:10.1016/j.tox.2011.09.015. Abstract -McWilliam, S.J.; Antoine, D.J.; Turner, M.; Sabbisetti, V.; Bonventre, J.V.; Park, B.K.; Smyth, R.L.; Pirmohamed, M. Urinary Kim-1 As A Biomarker of Aminoglycoside-Induced Nephrotoxicity in Premature Neonates. Pediatric Research. 70(5supplement):107, 2011. doi:10.1203/01.pdr.0000403893.61640.b6. Abstract & oral presentation at European Society for Paediatric Research, October 2011
Start Year 2009
 
Description Chelsea and Westminster (Sam Nightingale) 
Organisation Chelsea and Westminster Hospital NHS Foundation Trust
Department St Stephen's AIDS Trust
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Charity/Non Profit 
PI Contribution Participant in two multi-site studies lead by Dr Sam Nightingale (Clinical Fellow) who has attended for Site Initiation Visit and provides ongoing support to the clinical team: A) CNS Penetration of Antiretrovirals B) The CNS as a sanctuary site for HIV
Collaborator Contribution 31 patients were recruited to study A and 3 patient have been recruited to study B
Impact 31 patients were recruited to Study A of PARTITION and 3 patients were recruited to study B of PARTITION. Analysis of samples is ongoing.
Start Year 2012
 
Description Collaboration with National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institute of Health (John Reynolds) 
Organisation National Institutes of Health (NIH)
Department National Institute of Arthritis and Musculoskeletal and Skin Diseases
Country United States of America 
Sector Public 
PI Contribution None - training collaboration for the benefit of John Reynolds
Collaborator Contribution Training in Using Animal Models of SLE to Test Novel Agents
Impact Training in animal models received, access to facilities at NIH
Start Year 2014
 
Description Data Analysis Discussion (James McCaffrey) 
Organisation ICON
Country Ireland, Republic of 
Sector Private 
PI Contribution Data
Collaborator Contribution Discussion with Cyril Clarke (ICON) helped in the initial stages of data analysis for the AKI paper that has been submitted for publication in October 2014.
Impact Submission of paper for publication in June 2014
Start Year 2014
 
Description Detection of drug antibodies (Meghna Jani) 
Organisation Sanquin
Country Netherlands, Kingdom of the 
Sector Charity/Non Profit 
PI Contribution Contacting scientific team in The Netherlands, establishing collaboration, negotiating a feasible price for detection of drug antibodies.
Collaborator Contribution Partners provided service of measurement of drug antibodies using radioimmunoassay
Impact Outcomes of collaboration being evaluated at present
Start Year 2013
 
Description Detection of drug antibodies/Centre for Health Economics , University of Manchester (Meghna Jani) 
Organisation University of Manchester
Department Centre for Health Economics
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Academic/University 
PI Contribution Non-clinical PhD student and Meghna Jani to collaborate to establish to health economic feasibility of immunogenicity testing
Collaborator Contribution Health economics modelling of immunogenicity testing in the UK
Impact Outcomes of collaboration being evaluated at present
Start Year 2014
 
Description Drug induced pneumonitis in rheumatoid arthritis patients (James Bluett) 
Organisation Barnsley Hospital NHS Foundation Trust
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Hospitals 
PI Contribution Multi-centred study with multiple NHS sites. Genetic testing of samples
Collaborator Contribution Recruitment of patients
Impact Testing of samples ongoing
Start Year 2013
 
Description Drug induced pneumonitis in rheumatoid arthritis patients (James Bluett) 
Organisation Betsi Cadwaladr University Health Board
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Public 
PI Contribution Multi-centred study with multiple NHS sites. Genetic testing of samples
Collaborator Contribution Recruitment of patients
Impact Testing of samples ongoing
Start Year 2013
 
Description Drug induced pneumonitis in rheumatoid arthritis patients (James Bluett) 
Organisation Betsi Cadwaladr University Health Board
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Public 
PI Contribution Multi-centred study with multiple NHS sites. Genetic testing of samples
Collaborator Contribution Recruitment of patients
Impact Testing of samples ongoing
Start Year 2013
 
Description Drug induced pneumonitis in rheumatoid arthritis patients (James Bluett) 
Organisation Blackpool Teaching Hospitals NHS Foundation Trust
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Public 
PI Contribution Multi-centred study with multiple NHS sites. Genetic testing of samples
Collaborator Contribution Recruitment of patients
Impact Testing of samples ongoing
Start Year 2013
 
Description Drug induced pneumonitis in rheumatoid arthritis patients (James Bluett) 
Organisation Cambridge University Hospitals NHS Foundation Trust
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Public 
PI Contribution Multi-centred study with multiple NHS sites. Genetic testing of samples
Collaborator Contribution Recruitment of patients
Impact Testing of samples ongoing
Start Year 2013
 
Description Drug induced pneumonitis in rheumatoid arthritis patients (James Bluett) 
Organisation City Hospitals Sunderland NHS Foundation Trust
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Public 
PI Contribution Multi-centred study with multiple NHS sites. Genetic testing of samples
Collaborator Contribution Recruitment of patients
Impact Testing of samples ongoing
Start Year 2013
 
Description Drug induced pneumonitis in rheumatoid arthritis patients (James Bluett) 
Organisation Derby Teaching Hospitals NHS Foundation Trust
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Public 
PI Contribution Multi-centred study with multiple NHS sites. Genetic testing of samples
Collaborator Contribution Recruitment of patients
Impact Testing of samples ongoing
Start Year 2013
 
Description Drug induced pneumonitis in rheumatoid arthritis patients (James Bluett) 
Organisation East Cheshire NHS Trust
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Public 
PI Contribution Multi-centred study with multiple NHS sites. Genetic testing of samples
Collaborator Contribution Recruitment of patients
Impact Testing of samples ongoing
Start Year 2013
 
Description Drug induced pneumonitis in rheumatoid arthritis patients (James Bluett) 
Organisation Gateshead Health NHS Foundation Trust
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Public 
PI Contribution Multi-centred study with multiple NHS sites. Genetic testing of samples
Collaborator Contribution Recruitment of patients
Impact Testing of samples ongoing
Start Year 2013
 
Description Drug induced pneumonitis in rheumatoid arthritis patients (James Bluett) 
Organisation Hampshire Hospitals NHS Foundation Trust
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Public 
PI Contribution Multi-centred study with multiple NHS sites. Genetic testing of samples
Collaborator Contribution Recruitment of patients
Impact Testing of samples ongoing
Start Year 2013
 
Description Drug induced pneumonitis in rheumatoid arthritis patients (James Bluett) 
Organisation King's Mill Hospital
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Hospitals 
PI Contribution Multi-centred study with multiple NHS sites. Genetic testing of samples
Collaborator Contribution Recruitment of patients
Impact Testing of samples ongoing
Start Year 2013
 
Description Drug induced pneumonitis in rheumatoid arthritis patients (James Bluett) 
Organisation Lancashire Care NHS Foundation Trust
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Public 
PI Contribution Multi-centred study with multiple NHS sites. Genetic testing of samples
Collaborator Contribution Recruitment of patients
Impact Testing of samples ongoing
Start Year 2013
 
Description Drug induced pneumonitis in rheumatoid arthritis patients (James Bluett) 
Organisation Leeds Teaching Hospitals NHS Trust
Department Experimental Medicine Cancer Centre
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Charity/Non Profit 
PI Contribution Multi-centred study with multiple NHS sites. Genetic testing of samples
Collaborator Contribution Recruitment of patients
Impact Testing of samples ongoing
Start Year 2013
 
Description Drug induced pneumonitis in rheumatoid arthritis patients (James Bluett) 
Organisation Maidstone and Tunbridge Wells NHS Trust
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Public 
PI Contribution Multi-centred study with multiple NHS sites. Genetic testing of samples
Collaborator Contribution Recruitment of patients
Impact Testing of samples ongoing
Start Year 2013
 
Description Drug induced pneumonitis in rheumatoid arthritis patients (James Bluett) 
Organisation Manchester University NHS Foundation Trust
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Public 
PI Contribution Multi-centred study with multiple NHS sites. Genetic testing of samples
Collaborator Contribution Recruitment of patients
Impact Testing of samples ongoing
Start Year 2013
 
Description Drug induced pneumonitis in rheumatoid arthritis patients (James Bluett) 
Organisation NHS Lanarkshire
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Public 
PI Contribution Multi-centred study with multiple NHS sites. Genetic testing of samples
Collaborator Contribution Recruitment of patients
Impact Testing of samples ongoing
Start Year 2013
 
Description Drug induced pneumonitis in rheumatoid arthritis patients (James Bluett) 
Organisation Newcastle upon Tyne Hospitals NHS Foundation Trust
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Public 
PI Contribution Multi-centred study with multiple NHS sites. Genetic testing of samples
Collaborator Contribution Recruitment of patients
Impact Testing of samples ongoing
Start Year 2013
 
Description Drug induced pneumonitis in rheumatoid arthritis patients (James Bluett) 
Organisation North Cumbria University Hospitals NHS Trust
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Public 
PI Contribution Multi-centred study with multiple NHS sites. Genetic testing of samples
Collaborator Contribution Recruitment of patients
Impact Testing of samples ongoing
Start Year 2013
 
Description Drug induced pneumonitis in rheumatoid arthritis patients (James Bluett) 
Organisation Northumbria Healthcare NHS Foundation Trust
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Public 
PI Contribution Multi-centred study with multiple NHS sites. Genetic testing of samples
Collaborator Contribution Recruitment of patients
Impact Testing of samples ongoing
Start Year 2013
 
Description Drug induced pneumonitis in rheumatoid arthritis patients (James Bluett) 
Organisation Pennine Acute Hospitals NHS Trust
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Public 
PI Contribution Multi-centred study with multiple NHS sites. Genetic testing of samples
Collaborator Contribution Recruitment of patients
Impact Testing of samples ongoing
Start Year 2013
 
Description Drug induced pneumonitis in rheumatoid arthritis patients (James Bluett) 
Organisation Pennine MSK Partnership Ltd
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Private 
PI Contribution Multi-centred study with multiple NHS sites. Genetic testing of samples
Collaborator Contribution Recruitment of patients
Impact Testing of samples ongoing
Start Year 2013
 
Description Drug induced pneumonitis in rheumatoid arthritis patients (James Bluett) 
Organisation Plymouth Hospitals NHS Trust
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Public 
PI Contribution Multi-centred study with multiple NHS sites. Genetic testing of samples
Collaborator Contribution Recruitment of patients
Impact Testing of samples ongoing
Start Year 2013
 
Description Drug induced pneumonitis in rheumatoid arthritis patients (James Bluett) 
Organisation Salford Royal NHS Foundation Trust
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Public 
PI Contribution Multi-centred study with multiple NHS sites. Genetic testing of samples
Collaborator Contribution Recruitment of patients
Impact Testing of samples ongoing
Start Year 2013
 
Description Drug induced pneumonitis in rheumatoid arthritis patients (James Bluett) 
Organisation Sheffield Teaching Hospitals NHS Foundation Trust
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Public 
PI Contribution Multi-centred study with multiple NHS sites. Genetic testing of samples
Collaborator Contribution Recruitment of patients
Impact Testing of samples ongoing
Start Year 2013
 
Description Drug induced pneumonitis in rheumatoid arthritis patients (James Bluett) 
Organisation South Warwickshire NHS Foundation Trust
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Public 
PI Contribution Multi-centred study with multiple NHS sites. Genetic testing of samples
Collaborator Contribution Recruitment of patients
Impact Testing of samples ongoing
Start Year 2013
 
Description Drug induced pneumonitis in rheumatoid arthritis patients (James Bluett) 
Organisation Staffordshire and Stoke On Trent Partnership NHS Trust
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Public 
PI Contribution Multi-centred study with multiple NHS sites. Genetic testing of samples
Collaborator Contribution Recruitment of patients
Impact Testing of samples ongoing
Start Year 2013
 
Description Drug induced pneumonitis in rheumatoid arthritis patients (James Bluett) 
Organisation The Dudley Group NHS Foundation Trust
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Public 
PI Contribution Multi-centred study with multiple NHS sites. Genetic testing of samples
Collaborator Contribution Recruitment of patients
Impact Testing of samples ongoing
Start Year 2013
 
Description Drug induced pneumonitis in rheumatoid arthritis patients (James Bluett) 
Organisation University Hospitals Birmingham NHS Foundation Trust
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Public 
PI Contribution Multi-centred study with multiple NHS sites. Genetic testing of samples
Collaborator Contribution Recruitment of patients
Impact Testing of samples ongoing
Start Year 2013
 
Description Drug induced pneumonitis in rheumatoid arthritis patients (James Bluett) 
Organisation University Hospitals of Morecambe Bay NHS Foundation Trust
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Public 
PI Contribution Multi-centred study with multiple NHS sites. Genetic testing of samples
Collaborator Contribution Recruitment of patients
Impact Testing of samples ongoing
Start Year 2013
 
Description Drug induced pneumonitis in rheumatoid arthritis patients (James Bluett) 
Organisation Western Health and Social Care Trust
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Public 
PI Contribution Multi-centred study with multiple NHS sites. Genetic testing of samples
Collaborator Contribution Recruitment of patients
Impact Testing of samples ongoing
Start Year 2013
 
Description Drug induced pneumonitis in rheumatoid arthritis patients (James Bluett) 
Organisation York Teaching Hospital NHS Foundation Trust
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Public 
PI Contribution Multi-centred study with multiple NHS sites. Genetic testing of samples
Collaborator Contribution Recruitment of patients
Impact Testing of samples ongoing
Start Year 2013
 
Description GSK PKPD modelling collaboration (Stephen McWilliam) 
Organisation GlaxoSmithKline (GSK)
Country Global 
Sector Private 
PI Contribution Stephen McWilliam provided data and time.
Collaborator Contribution GSK provided modelling software, training and support.
Impact No outcomes as yet. Plan is to produce a publication.
Start Year 2013
 
Description ICON observation (Amy Foulkes) 
Organisation ICON
Country Ireland, Republic of 
Sector Private 
PI Contribution None
Collaborator Contribution Opportunity to attend meetings of pre-clinical trial design/discussion and follow up with observation of Phase I clinical trial in dermatology
Impact Personal learning for Fellow
Start Year 2012
 
Description Immunome Protein Array for Autoantibody detection in the circumstance of oncology immunotherapy toxicity (Munir Pirmohamed/ Anna Olsson-Brown) 
Organisation Sengenics
Country Singapore, Republic of 
Sector Private 
PI Contribution Study design and sample provision for pilot study
Collaborator Contribution provision of specific test for pilot study
Impact pending
Start Year 2016
 
Description Kindling rat model of epilepsy with pharmacological intervention (Lauren Walker) 
Organisation Mario Negri Institute for Pharmacological Research
Department Consorzio Mario Negri Sud (CMNS)
Country Italy, Italian Republic 
Sector Charity/Non Profit 
PI Contribution The samples were analysed by liquid chromatography tandem mass spectrometry at the University of Liverpool by Dr Dan Antoine. Lauren Walker (supervised by Dr Dan Antoine) undertook the interpretation of the LCMS/MS data from the samples
Collaborator Contribution Annamaria Vezzani (Mario Negri) provided brain and blood samples for analysis of rats with epilepsy taken 7, 15 and 90 days after the onset of disease. Three experimental groups were included; controls, epileptic rats and epileptic rats treated with novel immunomodulatory drugs.
Impact The data is being incorporated into a paper, combining multiple animal studies with human data and intervention animal studies, for submission to Nature Medicine
Start Year 2014
 
Description King's College Hospital London (Sam Nightingale) 
Organisation King's College Hospital NHS Foundation Trust (NCH)
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Academic/University 
PI Contribution Participants in a multi site study lead by Dr Sam Nightingale (Clinical Fellow) who has attended for Site Initiation Visit and provides ongoing support to the clinical team : A) CNS Penetration of Antiretrovirals B) The CNS as a sanctuary site for HIV
Collaborator Contribution 8 patients were recruited to Study A of PARTITION and 2 patients were recruited to study B of PARTITION.
Impact 8 patients were recruited to Study A of PARTITION and 2 patients were recruited to study B of PARTITION. Analysis of samples is ongoing.
Start Year 2013
 
Description Leeder collaboration (Stephen McWilliam) 
Organisation Children's Mercy Hospital
Country United States of America 
Sector Hospitals 
PI Contribution The collaborator has provided us with samples for analysis
Collaborator Contribution The collaborators will contribute through co-authoring research papers and analysis of results
Impact - McWilliam SJ, Antoine DJ, Sabbisetti V, Pearce RE, Jorgensen AL, Lin Y, Leeder JS, Bonventre JV, Smyth RL, Pirmohamed M. Reference intervals for urinary renal injury biomarkers KIM-1 and NGAL in healthy children. Biomark Med. 2014, 8(10):1189-1197
Start Year 2012
 
Description Leeds General Infirmary (Sam Nightingale) 
Organisation Leeds Teaching Hospitals NHS Trust
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Public 
PI Contribution Participant in two multi-site studies lead by Dr Sam Nightingale (Clinical Fellow) who has attended for Site Initiation Visit and provides ongoing support to the clinical team: A) CNS Penetration of Antiretrovirals B) The CNS as a sanctuary site for HIV
Collaborator Contribution 14 patients were recruited to Study A of PARTITION and 3 patients were recruited to study B of PARTITION.
Impact 14 patients were recruited to Study A of PARTITION and 3 patients were recruited to study B of PARTITION. Analysis of samples is ongoing.
Start Year 2012
 
Description MRC CDSS-AZ collaboration (Richard Kia) 
Organisation AstraZeneca
Department Research and Development AstraZeneca
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Private 
PI Contribution Experimental data from attempts to derive induced pluripotent stem cells using different methodology.
Collaborator Contribution Experimental data from attempts to derive induced pluripotent stem cells using different methodology to ours and also technical expertise in stem cell culture techniques
Impact Publication of a review paper with a listed co-author from AZ
Start Year 2011
 
Description MRC CDSS-MRC Toxicology Unit, Leicester (Richard Kia) 
Organisation Medical Research Council (MRC)
Department MRC Toxicology Unit
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Public 
PI Contribution MRC CDSS team will provide experimental samples for analysis of microRNA profiles using the Agilent microRNA microarray platform in MRC Toxicology Unit.
Collaborator Contribution MRC Toxicology Unit will provide technical expertise and bear the costs of the analyses.
Impact It is hoped that the MRC CDSS will share experimental data that will inform the development of a better in vitro liver model for drug screening.
Start Year 2013
 
Description MRC CDSS-University Hospital Aintree collaboration (Richard Kia) 
Organisation Aintree University Hospital NHS Foundation Trust
Department Hepatobiliary Surgical Department
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Hospitals 
PI Contribution Not directly by Richard Kia but potential data by other members of his team that could inform clinical practice
Collaborator Contribution Provision of liver resections and potentially other clinical material
Impact None Yet
Start Year 2011
 
Description Manchester MSK BRU (Sarah Skeoch) 
Organisation National Institute for Health Research
Department NIHR Manchester Musculoskeletal Biomedical Research Unit
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Public 
PI Contribution None
Collaborator Contribution Part of the research project is funded by the BRU approx. £50,000
Impact No outputs yet
Start Year 2012
 
Description Measurement of Methotrexate and 7-OH-methotrexate levels in patients with rheumatoid arthritis.(James Bluett) 
Organisation Manchester University NHS Foundation Trust
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Public 
PI Contribution Measurement of MTX/7-OH-MTX levels in patients with rheumatoid arthritis
Collaborator Contribution Samples were provided from patients with rheumatoid arthritis
Impact Measurement of methotrexate levels
Start Year 2013
 
Description Measurement of Methotrexate and 7-OH-methotrexate levels in patients with rheumatoid arthritis.(James Bluett) 
Organisation University of Manchester
Department Centre for Advanced Discovery and Experimental Therapeutics
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Hospitals 
PI Contribution Measurement of MTX/7-OH-MTX levels in patients with rheumatoid arthritis
Collaborator Contribution Samples were provided from patients with rheumatoid arthritis
Impact Measurement of methotrexate levels
Start Year 2013
 
Description Member of Validation of translational imaging methods in drug safety assessment (TRISTAN) consortium on successful EU Innovation in Medicine Grant (Sarah Skeoch) 
Organisation Alderley Imaging Ltd
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Private 
PI Contribution Sarah Skeoch was a member of a consortium which successful applied for an IMI-2 grant (value approximately 22million Euros). Sarah Skeoch, and colleagues at the University of Manchester, co-wrote the application. They are writing a review article, one of the first deliverables on the grant and are setting up and co-ordinating a multi-centre study in rheumatology and drug induced lung disease in collaboration with other centres in the UK.
Collaborator Contribution Large consortium with input in clinical and pre-clinical work in a number of aspects of developing imaging biomarkers for drug toxicity.
Impact None yet
Start Year 2017
 
Description Member of Validation of translational imaging methods in drug safety assessment (TRISTAN) consortium on successful EU Innovation in Medicine Grant (Sarah Skeoch) 
Organisation Bioxydn
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Private 
PI Contribution Sarah Skeoch was a member of a consortium which successful applied for an IMI-2 grant (value approximately 22million Euros). Sarah Skeoch, and colleagues at the University of Manchester, co-wrote the application. They are writing a review article, one of the first deliverables on the grant and are setting up and co-ordinating a multi-centre study in rheumatology and drug induced lung disease in collaboration with other centres in the UK.
Collaborator Contribution Large consortium with input in clinical and pre-clinical work in a number of aspects of developing imaging biomarkers for drug toxicity.
Impact None yet
Start Year 2017
 
Description Member of Validation of translational imaging methods in drug safety assessment (TRISTAN) consortium on successful EU Innovation in Medicine Grant (Sarah Skeoch) 
Organisation Chalmers University of Technology
Country Sweden, Kingdom of 
Sector Academic/University 
PI Contribution Sarah Skeoch was a member of a consortium which successful applied for an IMI-2 grant (value approximately 22million Euros). Sarah Skeoch, and colleagues at the University of Manchester, co-wrote the application. They are writing a review article, one of the first deliverables on the grant and are setting up and co-ordinating a multi-centre study in rheumatology and drug induced lung disease in collaboration with other centres in the UK.
Collaborator Contribution Large consortium with input in clinical and pre-clinical work in a number of aspects of developing imaging biomarkers for drug toxicity.
Impact None yet
Start Year 2017
 
Description Member of Validation of translational imaging methods in drug safety assessment (TRISTAN) consortium on successful EU Innovation in Medicine Grant (Sarah Skeoch) 
Organisation European Organisation for Research and Treatment of Cancer (EORTC)
Country European Union (EU) 
Sector Charity/Non Profit 
PI Contribution Sarah Skeoch was a member of a consortium which successful applied for an IMI-2 grant (value approximately 22million Euros). Sarah Skeoch, and colleagues at the University of Manchester, co-wrote the application. They are writing a review article, one of the first deliverables on the grant and are setting up and co-ordinating a multi-centre study in rheumatology and drug induced lung disease in collaboration with other centres in the UK.
Collaborator Contribution Large consortium with input in clinical and pre-clinical work in a number of aspects of developing imaging biomarkers for drug toxicity.
Impact None yet
Start Year 2017
 
Description Member of Validation of translational imaging methods in drug safety assessment (TRISTAN) consortium on successful EU Innovation in Medicine Grant (Sarah Skeoch) 
Organisation Lund University
Country Sweden, Kingdom of 
Sector Academic/University 
PI Contribution Sarah Skeoch was a member of a consortium which successful applied for an IMI-2 grant (value approximately 22million Euros). Sarah Skeoch, and colleagues at the University of Manchester, co-wrote the application. They are writing a review article, one of the first deliverables on the grant and are setting up and co-ordinating a multi-centre study in rheumatology and drug induced lung disease in collaboration with other centres in the UK.
Collaborator Contribution Large consortium with input in clinical and pre-clinical work in a number of aspects of developing imaging biomarkers for drug toxicity.
Impact None yet
Start Year 2017
 
Description Member of Validation of translational imaging methods in drug safety assessment (TRISTAN) consortium on successful EU Innovation in Medicine Grant (Sarah Skeoch) 
Organisation Radboud University Nijmegen
Country Netherlands, Kingdom of the 
Sector Academic/University 
PI Contribution Sarah Skeoch was a member of a consortium which successful applied for an IMI-2 grant (value approximately 22million Euros). Sarah Skeoch, and colleagues at the University of Manchester, co-wrote the application. They are writing a review article, one of the first deliverables on the grant and are setting up and co-ordinating a multi-centre study in rheumatology and drug induced lung disease in collaboration with other centres in the UK.
Collaborator Contribution Large consortium with input in clinical and pre-clinical work in a number of aspects of developing imaging biomarkers for drug toxicity.
Impact None yet
Start Year 2017
 
Description Member of Validation of translational imaging methods in drug safety assessment (TRISTAN) consortium on successful EU Innovation in Medicine Grant (Sarah Skeoch) 
Organisation Truly Labs AB
Country Sweden, Kingdom of 
Sector Private 
PI Contribution Sarah Skeoch was a member of a consortium which successful applied for an IMI-2 grant (value approximately 22million Euros). Sarah Skeoch, and colleagues at the University of Manchester, co-wrote the application. They are writing a review article, one of the first deliverables on the grant and are setting up and co-ordinating a multi-centre study in rheumatology and drug induced lung disease in collaboration with other centres in the UK.
Collaborator Contribution Large consortium with input in clinical and pre-clinical work in a number of aspects of developing imaging biomarkers for drug toxicity.
Impact None yet
Start Year 2017
 
Description Member of Validation of translational imaging methods in drug safety assessment (TRISTAN) consortium on successful EU Innovation in Medicine Grant (Sarah Skeoch) 
Organisation University Medical Center Gronigen
Country Netherlands, Kingdom of the 
Sector Hospitals 
PI Contribution Sarah Skeoch was a member of a consortium which successful applied for an IMI-2 grant (value approximately 22million Euros). Sarah Skeoch, and colleagues at the University of Manchester, co-wrote the application. They are writing a review article, one of the first deliverables on the grant and are setting up and co-ordinating a multi-centre study in rheumatology and drug induced lung disease in collaboration with other centres in the UK.
Collaborator Contribution Large consortium with input in clinical and pre-clinical work in a number of aspects of developing imaging biomarkers for drug toxicity.
Impact None yet
Start Year 2017
 
Description Member of Validation of translational imaging methods in drug safety assessment (TRISTAN) consortium on successful EU Innovation in Medicine Grant (Sarah Skeoch) 
Organisation University of Burgundy
Country France, French Republic 
Sector Academic/University 
PI Contribution Sarah Skeoch was a member of a consortium which successful applied for an IMI-2 grant (value approximately 22million Euros). Sarah Skeoch, and colleagues at the University of Manchester, co-wrote the application. They are writing a review article, one of the first deliverables on the grant and are setting up and co-ordinating a multi-centre study in rheumatology and drug induced lung disease in collaboration with other centres in the UK.
Collaborator Contribution Large consortium with input in clinical and pre-clinical work in a number of aspects of developing imaging biomarkers for drug toxicity.
Impact None yet
Start Year 2017
 
Description Member of Validation of translational imaging methods in drug safety assessment (TRISTAN) consortium on successful EU Innovation in Medicine Grant (Sarah Skeoch) 
Organisation University of Leeds
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Academic/University 
PI Contribution Sarah Skeoch was a member of a consortium which successful applied for an IMI-2 grant (value approximately 22million Euros). Sarah Skeoch, and colleagues at the University of Manchester, co-wrote the application. They are writing a review article, one of the first deliverables on the grant and are setting up and co-ordinating a multi-centre study in rheumatology and drug induced lung disease in collaboration with other centres in the UK.
Collaborator Contribution Large consortium with input in clinical and pre-clinical work in a number of aspects of developing imaging biomarkers for drug toxicity.
Impact None yet
Start Year 2017
 
Description Member of Validation of translational imaging methods in drug safety assessment (TRISTAN) consortium on successful EU Innovation in Medicine Grant (Sarah Skeoch) 
Organisation University of Manchester
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Academic/University 
PI Contribution Sarah Skeoch was a member of a consortium which successful applied for an IMI-2 grant (value approximately 22million Euros). Sarah Skeoch, and colleagues at the University of Manchester, co-wrote the application. They are writing a review article, one of the first deliverables on the grant and are setting up and co-ordinating a multi-centre study in rheumatology and drug induced lung disease in collaboration with other centres in the UK.
Collaborator Contribution Large consortium with input in clinical and pre-clinical work in a number of aspects of developing imaging biomarkers for drug toxicity.
Impact None yet
Start Year 2017
 
Description Member of Validation of translational imaging methods in drug safety assessment (TRISTAN) consortium on successful EU Innovation in Medicine Grant (Sarah Skeoch) 
Organisation University of Sheffield
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Academic/University 
PI Contribution Sarah Skeoch was a member of a consortium which successful applied for an IMI-2 grant (value approximately 22million Euros). Sarah Skeoch, and colleagues at the University of Manchester, co-wrote the application. They are writing a review article, one of the first deliverables on the grant and are setting up and co-ordinating a multi-centre study in rheumatology and drug induced lung disease in collaboration with other centres in the UK.
Collaborator Contribution Large consortium with input in clinical and pre-clinical work in a number of aspects of developing imaging biomarkers for drug toxicity.
Impact None yet
Start Year 2017
 
Description Multi centre study suported by the CLRN (Sarah Skeoch) 
Organisation East Cheshire NHS Trust
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Public 
PI Contribution We applied to the local CLRN for support for our clinical study and have set up several recruiting sites and primary care trusts.
Collaborator Contribution Patient Recruitment
Impact None yet
Start Year 2012
 
Description Multi centre study suported by the CLRN (Sarah Skeoch) 
Organisation Manchester University NHS Foundation Trust
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Public 
PI Contribution We applied to the local CLRN for support for our clinical study and have set up several recruiting sites and primary care trusts.
Collaborator Contribution Patient Recruitment
Impact None yet
Start Year 2012
 
Description Multi centre study suported by the CLRN (Sarah Skeoch) 
Organisation Manchester University NHS Foundation Trust
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Public 
PI Contribution We applied to the local CLRN for support for our clinical study and have set up several recruiting sites and primary care trusts.
Collaborator Contribution Patient Recruitment
Impact None yet
Start Year 2012
 
Description Multi centre study suported by the CLRN (Sarah Skeoch) 
Organisation NHS Manchester
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Public 
PI Contribution We applied to the local CLRN for support for our clinical study and have set up several recruiting sites and primary care trusts.
Collaborator Contribution Patient Recruitment
Impact None yet
Start Year 2012
 
Description Multi centre study suported by the CLRN (Sarah Skeoch) 
Organisation NHS Oldham CCG
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Public 
PI Contribution We applied to the local CLRN for support for our clinical study and have set up several recruiting sites and primary care trusts.
Collaborator Contribution Patient Recruitment
Impact None yet
Start Year 2012
 
Description Multi centre study suported by the CLRN (Sarah Skeoch) 
Organisation NHS Salford CCG
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Public 
PI Contribution We applied to the local CLRN for support for our clinical study and have set up several recruiting sites and primary care trusts.
Collaborator Contribution Patient Recruitment
Impact None yet
Start Year 2012
 
Description Multi centre study suported by the CLRN (Sarah Skeoch) 
Organisation National Institute for Health Research
Department NIHR CLAHRC for Greater Manchester
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Public 
PI Contribution We applied to the local CLRN for support for our clinical study and have set up several recruiting sites and primary care trusts.
Collaborator Contribution Patient Recruitment
Impact None yet
Start Year 2012
 
Description Multi centre study suported by the CLRN (Sarah Skeoch) 
Organisation North Manchester General Hospital
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Hospitals 
PI Contribution We applied to the local CLRN for support for our clinical study and have set up several recruiting sites and primary care trusts.
Collaborator Contribution Patient Recruitment
Impact None yet
Start Year 2012
 
Description Multi centre study suported by the CLRN (Sarah Skeoch) 
Organisation Pennine MSK Partnership Ltd
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Private 
PI Contribution We applied to the local CLRN for support for our clinical study and have set up several recruiting sites and primary care trusts.
Collaborator Contribution Patient Recruitment
Impact None yet
Start Year 2012
 
Description Multi centre study suported by the CLRN (Sarah Skeoch) 
Organisation Salford Royal NHS Foundation Trust
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Public 
PI Contribution We applied to the local CLRN for support for our clinical study and have set up several recruiting sites and primary care trusts.
Collaborator Contribution Patient Recruitment
Impact None yet
Start Year 2012
 
Description Multi-centre observational study (Meghna Jani) 
Organisation Aintree University Hospital NHS Foundation Trust
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Hospitals 
PI Contribution Approached sites for recruitment, completed R&D process, site initiation calls, site induction and supporting research teams. (Meghna Jani)
Collaborator Contribution Patient recruitment
Impact Recruiting patients to a multi-centre national study. Results awaited after completion
Start Year 2013
 
Description Multi-centre observational study (Meghna Jani) 
Organisation Basildon and Thurrock University Hospitals NHS Foundation Trust
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Public 
PI Contribution Approached sites for recruitment, completed R&D process, site initiation calls, site induction and supporting research teams. (Meghna Jani)
Collaborator Contribution Patient recruitment
Impact Recruiting patients to a multi-centre national study. Results awaited after completion
Start Year 2013
 
Description Multi-centre observational study (Meghna Jani) 
Organisation Haywood Hospital
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Hospitals 
PI Contribution Approached sites for recruitment, completed R&D process, site initiation calls, site induction and supporting research teams. (Meghna Jani)
Collaborator Contribution Patient recruitment
Impact Recruiting patients to a multi-centre national study. Results awaited after completion
Start Year 2013
 
Description Multi-centre observational study (Meghna Jani) 
Organisation Ipswich Hospital NHS Trust
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Public 
PI Contribution Approached sites for recruitment, completed R&D process, site initiation calls, site induction and supporting research teams. (Meghna Jani)
Collaborator Contribution Patient recruitment
Impact Recruiting patients to a multi-centre national study. Results awaited after completion
Start Year 2013
 
Description Multi-centre observational study (Meghna Jani) 
Organisation Manchester University NHS Foundation Trust
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Public 
PI Contribution Approached sites for recruitment, completed R&D process, site initiation calls, site induction and supporting research teams. (Meghna Jani)
Collaborator Contribution Patient recruitment
Impact Recruiting patients to a multi-centre national study. Results awaited after completion
Start Year 2013
 
Description Multi-centre observational study (Meghna Jani) 
Organisation Manchester University NHS Foundation Trust
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Public 
PI Contribution Approached sites for recruitment, completed R&D process, site initiation calls, site induction and supporting research teams. (Meghna Jani)
Collaborator Contribution Patient recruitment
Impact Recruiting patients to a multi-centre national study. Results awaited after completion
Start Year 2013
 
Description Multi-centre observational study (Meghna Jani) 
Organisation Northern Devon Healthcare NHS Trust
Department North Devon Hospital
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Hospitals 
PI Contribution Approached sites for recruitment, completed R&D process, site initiation calls, site induction and supporting research teams. (Meghna Jani)
Collaborator Contribution Patient recruitment
Impact Recruiting patients to a multi-centre national study. Results awaited after completion
Start Year 2013
 
Description Multi-centre observational study (Meghna Jani) 
Organisation Pennine Acute Hospitals NHS Trust
Department Fairfield Hospital
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Hospitals 
PI Contribution Approached sites for recruitment, completed R&D process, site initiation calls, site induction and supporting research teams. (Meghna Jani)
Collaborator Contribution Patient recruitment
Impact Recruiting patients to a multi-centre national study. Results awaited after completion
Start Year 2013
 
Description Multi-centre observational study (Meghna Jani) 
Organisation Queen's Medical Centre
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Hospitals 
PI Contribution Approached sites for recruitment, completed R&D process, site initiation calls, site induction and supporting research teams. (Meghna Jani)
Collaborator Contribution Patient recruitment
Impact Recruiting patients to a multi-centre national study. Results awaited after completion
Start Year 2013
 
Description Multi-centre observational study (Meghna Jani) 
Organisation Royal National Hospital for Rheumatic Diseases
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Hospitals 
PI Contribution Approached sites for recruitment, completed R&D process, site initiation calls, site induction and supporting research teams. (Meghna Jani)
Collaborator Contribution Patient recruitment
Impact Recruiting patients to a multi-centre national study. Results awaited after completion
Start Year 2013
 
Description Multi-centre observational study (Meghna Jani) 
Organisation Salford Royal NHS Foundation Trust
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Public 
PI Contribution Approached sites for recruitment, completed R&D process, site initiation calls, site induction and supporting research teams. (Meghna Jani)
Collaborator Contribution Patient recruitment
Impact Recruiting patients to a multi-centre national study. Results awaited after completion
Start Year 2013
 
Description Multi-centre observational study (Meghna Jani) 
Organisation University Hospitals of Morecambe Bay NHS Foundation Trust
Department Royal Lancaster Infirmary
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Hospitals 
PI Contribution Approached sites for recruitment, completed R&D process, site initiation calls, site induction and supporting research teams. (Meghna Jani)
Collaborator Contribution Patient recruitment
Impact Recruiting patients to a multi-centre national study. Results awaited after completion
Start Year 2013
 
Description Multi-centre observational study (Meghna Jani) 
Organisation Wrightington, Wigan and Leigh NHS Foundation Trust
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Public 
PI Contribution Approached sites for recruitment, completed R&D process, site initiation calls, site induction and supporting research teams. (Meghna Jani)
Collaborator Contribution Patient recruitment
Impact Recruiting patients to a multi-centre national study. Results awaited after completion
Start Year 2013
 
Description North Manchester Hospital (Sam Nightingale) 
Organisation Pennine Acute Hospitals NHS Trust
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Public 
PI Contribution Participant in two multi-site studies lead by Dr Sam Nightingale (Clinical Fellow) who has attended for Site Initiation Visit and provides ongoing support to the clinical team : A) CNS Penetration of Antiretrovirals B) The CNS as a sanctuary site for HIV
Collaborator Contribution 25 patients were recruited to Study A of PARTITION and 5 patients were recruited to study B of PARTITION.
Impact 25 patients were recruited to Study A of PARTITION and 5 patients were recruited to study B of PARTITION. Analysis of samples is ongoing.
Start Year 2012
 
Description North Middlesex Hospital (Sam Nightingale) 
Organisation North Middlesex University Hospital NHS Trust
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Public 
PI Contribution Participant in two multi-site studies lead by Dr Sam Nightingale (Clinical Fellow) who has attended for Site Initiation Visit and provides ongoing support to the clinical team: A) CNS Penetration of Antiretrovirals B) The CNS as a sanctuary site for HIV
Collaborator Contribution 8 patients were recruited to Study A of PARTITION and 2 patients were recruited to study B of PARTITION.
Impact 8 patients were recruited to Study A of PARTITION and 2 patients were recruited to study B of PARTITION. Analysis of samples is ongoing.
Start Year 2012
 
Description PICME II Study (Vincent Yip) 
Organisation The Walton Centre NHS Foundation Trust
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Public 
PI Contribution Vincent Yip developed clinical protocol, ethics and CTA application.
Collaborator Contribution Walton Centre will review protocol, provide co-sponsorship and will provide facilities for study to be undertaken.
Impact None yet
Start Year 2013
 
Description PICME Study (Vincent Yip) 
Organisation Royal Liverpool and Broadgreen University Hospitals NHS Trust
Department Royal Liverpool Clinical Research Unit (CRU)
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Academic/University 
PI Contribution Vincent Yip developed the clinical protocol, ethics and CTA application. Clinical trial has now commenced with 7 out of 8 volunteers completing the study (2013).
Collaborator Contribution Review of clinical protocol, co-sponsorship, facilities, pharmacy
Impact None yet
Start Year 2012
 
Description PPS Study (Lauren Walker) 
Organisation The Walton Centre NHS Foundation Trust
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Public 
PI Contribution Lauren Walker designed the study, put together the protocol, patient leaflet and consent forms etc. and did the ethics application and attended the meeting. As a portfolio study Lauren Walker is assisted by a research nurse to recruit patients and collect samples.
Collaborator Contribution Active support from Walton Centre and CLRN nurse in recruiting patients
Impact Once collection of the samples is complete, they will be analysed and this will be incorporated into a scientific paper.
Start Year 2010
 
Description PSORT Psoriasis Stratification to Optimise Relevant Therapy (Amy Foulkes) 
Organisation GlaxoSmithKline (GSK)
Country Global 
Sector Private 
PI Contribution Major collaborative succsessful MRC bid with Amy Foulkes supervisors Dr Richard Warren and Professor Chris Griffiths. Amy Foulkes:- •Fellowship data formed pilot data for one of the two work streams of the successful bid. • Regularly attended GSK Stevenage site. Samples from her Fellowship have been processed there. She has also presented to GSK staff on behalf of the PSORT consortium prior to the successful bid. •Regularly attended QMUL London where data analysis is being completed with the Bioinformatics team. •Spent >4 weeks working with our collaborators at Newcastle University on laboratory sample processing
Collaborator Contribution The University of Manchester is coordinating this whole study, there are 2 work streams & Amy Foulke's data was pilot data for one of them. GSK and Newcastle are processing samples. QMUL are completing the data analysis Funding
Impact No outputs yet, Amy Foulke's data is likely to be published as the first output next year
Start Year 2013
 
Description PSORT Psoriasis Stratification to Optimise Relevant Therapy (Amy Foulkes) 
Organisation Newcastle University
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Academic/University 
PI Contribution Major collaborative succsessful MRC bid with Amy Foulkes supervisors Dr Richard Warren and Professor Chris Griffiths. Amy Foulkes:- •Fellowship data formed pilot data for one of the two work streams of the successful bid. • Regularly attended GSK Stevenage site. Samples from her Fellowship have been processed there. She has also presented to GSK staff on behalf of the PSORT consortium prior to the successful bid. •Regularly attended QMUL London where data analysis is being completed with the Bioinformatics team. •Spent >4 weeks working with our collaborators at Newcastle University on laboratory sample processing
Collaborator Contribution The University of Manchester is coordinating this whole study, there are 2 work streams & Amy Foulke's data was pilot data for one of them. GSK and Newcastle are processing samples. QMUL are completing the data analysis Funding
Impact No outputs yet, Amy Foulke's data is likely to be published as the first output next year
Start Year 2013
 
Description PSORT Psoriasis Stratification to Optimise Relevant Therapy (Amy Foulkes) 
Organisation Queen Mary University of London
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Academic/University 
PI Contribution Major collaborative succsessful MRC bid with Amy Foulkes supervisors Dr Richard Warren and Professor Chris Griffiths. Amy Foulkes:- •Fellowship data formed pilot data for one of the two work streams of the successful bid. • Regularly attended GSK Stevenage site. Samples from her Fellowship have been processed there. She has also presented to GSK staff on behalf of the PSORT consortium prior to the successful bid. •Regularly attended QMUL London where data analysis is being completed with the Bioinformatics team. •Spent >4 weeks working with our collaborators at Newcastle University on laboratory sample processing
Collaborator Contribution The University of Manchester is coordinating this whole study, there are 2 work streams & Amy Foulke's data was pilot data for one of them. GSK and Newcastle are processing samples. QMUL are completing the data analysis Funding
Impact No outputs yet, Amy Foulke's data is likely to be published as the first output next year
Start Year 2013
 
Description PSORT Psoriasis Stratification to Optimise Relevant Therapy (Amy Foulkes) 
Organisation University of Liverpool
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Academic/University 
PI Contribution Major collaborative succsessful MRC bid with Amy Foulkes supervisors Dr Richard Warren and Professor Chris Griffiths. Amy Foulkes:- •Fellowship data formed pilot data for one of the two work streams of the successful bid. • Regularly attended GSK Stevenage site. Samples from her Fellowship have been processed there. She has also presented to GSK staff on behalf of the PSORT consortium prior to the successful bid. •Regularly attended QMUL London where data analysis is being completed with the Bioinformatics team. •Spent >4 weeks working with our collaborators at Newcastle University on laboratory sample processing
Collaborator Contribution The University of Manchester is coordinating this whole study, there are 2 work streams & Amy Foulke's data was pilot data for one of them. GSK and Newcastle are processing samples. QMUL are completing the data analysis Funding
Impact No outputs yet, Amy Foulke's data is likely to be published as the first output next year
Start Year 2013
 
Description PSORT Psoriasis Stratification to Optimise Relevant Therapy (Amy Foulkes) 
Organisation University of Manchester
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Academic/University 
PI Contribution Major collaborative succsessful MRC bid with Amy Foulkes supervisors Dr Richard Warren and Professor Chris Griffiths. Amy Foulkes:- •Fellowship data formed pilot data for one of the two work streams of the successful bid. • Regularly attended GSK Stevenage site. Samples from her Fellowship have been processed there. She has also presented to GSK staff on behalf of the PSORT consortium prior to the successful bid. •Regularly attended QMUL London where data analysis is being completed with the Bioinformatics team. •Spent >4 weeks working with our collaborators at Newcastle University on laboratory sample processing
Collaborator Contribution The University of Manchester is coordinating this whole study, there are 2 work streams & Amy Foulke's data was pilot data for one of them. GSK and Newcastle are processing samples. QMUL are completing the data analysis Funding
Impact No outputs yet, Amy Foulke's data is likely to be published as the first output next year
Start Year 2013
 
Description Population PK of carbamazepine therapy (Vincent Yip) 
Organisation ICON
Country Ireland, Republic of 
Sector Private 
PI Contribution Study data
Collaborator Contribution ICON supported Vincent Yip with study/trial design and provided the licence for the NONMEM software in order to carry out a population PK of carbamazepine therapy.
Impact Data collection is now complete and a model being developed.
Start Year 2013
 
Description Proteomics & Pharmacokinetics Collaboration [Richard Myles Turner] 
Organisation University of Dundee
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Academic/University 
PI Contribution i) Undertaking iTRAQ proteomics experiments on samples provided from the University of Dundee, and sharing the generated data with our collaborators. ii) In vivo murine pharmacokinetics study carried out using novel dried blood spot sampling.
Collaborator Contribution Provision of relevant samples from wild-type and knock out murine models for the proteomics experiments
Impact Research results presented as a poster at the British Pharmacological Society Annual Winter meeting, 2016
Start Year 2014
 
Description Royal Liverpool University Hospital (Sam Nightingale) 
Organisation Royal Liverpool University Hospital
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Hospitals 
PI Contribution Co-Sponsor and participating site in two multi site studies conducted by Dr Sam Nightingale (Clinical Fellow) who works directly with the clinical team to recruit patients. 1) CNS Penetration of Antiretrovirals 2) The CNS as a Sanctuary Site for HIV
Collaborator Contribution Co-sponsor and recruitment of patients to these studies. 25 patients were recruited to Study A of PARTITION and 11 patients were recruited to study B of PARTITION.
Impact R&D support in the set up of further sites involved in this study. 25 patients were recruited to Study A of PARTITION and 11 patients were recruited to study B of PARTITION. Analysis of samples is ongoing.
Start Year 2011
 
Description Royal Liverpool and Broadgreen University Hospital Trust (Amy Foulkes) 
Organisation Royal Liverpool and Broadgreen University Hospitals NHS Trust
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Public 
PI Contribution Clinical collaboration for the collection of research patients. Sample analysis.
Collaborator Contribution Patient recruitment
Impact Clinical collaboration for the recruitment of patients. Patients recruited. Samples under analysis.
Start Year 2011
 
Description Royal Sussex County Hospital (Sam Nightingale) 
Organisation Brighton and Sussex University Hospitals NHS Trust
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Public 
PI Contribution Participant in 2 multi-site study lead by Dr Sam Nightingale (Clinical Fellow) who has attended for Site Initiation Visit and provides ongoing support to the clinical team : 1) CNS Penetration of Antiretrovirals 2) The CNS as a Sanctuary Site for HIV
Collaborator Contribution 31 patients were recruited to Study A of PARTITION and 11 patients were recruited to study B of PARTITION.
Impact 31 patients were recruited to Study A of PARTITION and 11 patients were recruited to study B of PARTITION. Analysis of samples is ongoing.
Start Year 2012
 
Description Royal Victoria Infirmary (Sam Nightingale) 
Organisation Royal Victoria Infirmary
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Hospitals 
PI Contribution Participant in two multi-site studies lead by Dr Sam Nightingale (Clinical Fellow) who has attended for Site Initiation Visit and provides ongoing support to the clinical team: 1) CNS Penetration of Antiretrovirals
Collaborator Contribution 3 patients were recruited to Study A of PARTITION
Impact 3 patients were recruited to Study A of PARTITION. Analysis of samples is ongoing.
Start Year 2012
 
Description Serum neurofilament analysis (Sam Nightingale) 
Organisation Queen Mary University of London
Department Blizard Institute
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Academic/University 
PI Contribution Samples Sam Nightingale has collected from the MRC funded PARTITION study will be analysed by the BLIZZARD institute using a novel assay for neurofilament detection in serum.
Collaborator Contribution Sam Nightingale is providing samples and they will perform the analysis using their unique assay.
Impact Work ongoing
Start Year 2012
 
Description St Mary's Hospital London (Sam Nightingale) 
Organisation Imperial College Healthcare NHS Trust
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Hospitals 
PI Contribution Participant in multi-site study lead by Dr Sam Nightingale (Clinical Fellow) who has attended for Site Initiation Visit and provides ongoing support to the clinical team: CNS Penetration of Antiretrovirals
Collaborator Contribution 17 patients were recruited to Study A of PARTITION
Impact 17 patients were recruited to Study A of PARTITION. Analysis of samples is ongoing.
Start Year 2012
 
Description Tampere (PPS Study) (Lauren Walker) 
Organisation Tampere University of Technology
Department Inpatient Telemetry Unit/Clinical Trials
Country Finland, Republic of 
Sector Academic/University 
PI Contribution None
Collaborator Contribution 50 post-seizure serum samples to to be contributed to PPS study.
Impact The samples have been analysed and the results will be incorporated into a scientific paper (in preparation)
Start Year 2012
 
Description The Walton Centre (Sam Nightingale) 
Organisation The Walton Centre NHS Foundation Trust
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Public 
PI Contribution Participant in a multi-site studies lead by Dr Sam Nightingale (Clinical Fellow) who has attended for Site Initiation Visit and provides ongoing support to the clinical team: 1) CNS Penetration of Antiretrovirals
Collaborator Contribution 3 patients were recruited to Study A of PARTITION.
Impact 3 patients were recruited to Study A of PARTITION. Analysis of samples is ongoing.
Start Year 2012
 
Description U-PGx Collaboration (Richard Turner) 
Organisation Bio.logis Genetic Information Management GMBH
Country Germany, Federal Republic of 
Sector Private 
PI Contribution Ubiquitous pharmacogenomics (U-PGx) is a large project approved by the EU Horizon 2020 Societal Challenges funding stream. Professor Sir Munir Pirmohamed and I are the UK Lead Investigators for this consortium. I have been involved since the project planning stage and assisted in the writing and reviewing of the grant application prior to acceptance. The project officially started on 1st January 2016 and I attended the Leiden kick-off meeting. We are involved in several work packages. Most importantly, the consortium will undertake a large prospective pharmacogenetics implementation study involving 8000 patients from January 2017; I am a co-investigator for the UK study site (1500 patients to be recruited) and have been heavily involved in the protocol development (work package 4). In addition, I have been involved in appointing a new pharmacist PhD fellow to the project, surveying the current knowledge and attitudes of UK clinicians regarding pharmacogenomics, selecting the genotype panel for the implementation study, and choosing the preferred 'easy-to-interpret' language that will be adopted into the genetic report for each patient (based on existing guidelines).
Collaborator Contribution The other partners of this consortium were involved in the grant application process and are now involved in delivering the project. In particular, the main clinical implementation study will be conducted at seven clinical sites across Europe, including the UK.
Impact No Impact yet
Start Year 2014
 
Description U-PGx Collaboration (Richard Turner) 
Organisation KNMP Holding B.V.
Country Netherlands, Kingdom of the 
Sector Private 
PI Contribution Ubiquitous pharmacogenomics (U-PGx) is a large project approved by the EU Horizon 2020 Societal Challenges funding stream. Professor Sir Munir Pirmohamed and I are the UK Lead Investigators for this consortium. I have been involved since the project planning stage and assisted in the writing and reviewing of the grant application prior to acceptance. The project officially started on 1st January 2016 and I attended the Leiden kick-off meeting. We are involved in several work packages. Most importantly, the consortium will undertake a large prospective pharmacogenetics implementation study involving 8000 patients from January 2017; I am a co-investigator for the UK study site (1500 patients to be recruited) and have been heavily involved in the protocol development (work package 4). In addition, I have been involved in appointing a new pharmacist PhD fellow to the project, surveying the current knowledge and attitudes of UK clinicians regarding pharmacogenomics, selecting the genotype panel for the implementation study, and choosing the preferred 'easy-to-interpret' language that will be adopted into the genetic report for each patient (based on existing guidelines).
Collaborator Contribution The other partners of this consortium were involved in the grant application process and are now involved in delivering the project. In particular, the main clinical implementation study will be conducted at seven clinical sites across Europe, including the UK.
Impact No Impact yet
Start Year 2014
 
Description U-PGx Collaboration (Richard Turner) 
Organisation Karolinska Institute
Country Sweden, Kingdom of 
Sector Academic/University 
PI Contribution Ubiquitous pharmacogenomics (U-PGx) is a large project approved by the EU Horizon 2020 Societal Challenges funding stream. Professor Sir Munir Pirmohamed and I are the UK Lead Investigators for this consortium. I have been involved since the project planning stage and assisted in the writing and reviewing of the grant application prior to acceptance. The project officially started on 1st January 2016 and I attended the Leiden kick-off meeting. We are involved in several work packages. Most importantly, the consortium will undertake a large prospective pharmacogenetics implementation study involving 8000 patients from January 2017; I am a co-investigator for the UK study site (1500 patients to be recruited) and have been heavily involved in the protocol development (work package 4). In addition, I have been involved in appointing a new pharmacist PhD fellow to the project, surveying the current knowledge and attitudes of UK clinicians regarding pharmacogenomics, selecting the genotype panel for the implementation study, and choosing the preferred 'easy-to-interpret' language that will be adopted into the genetic report for each patient (based on existing guidelines).
Collaborator Contribution The other partners of this consortium were involved in the grant application process and are now involved in delivering the project. In particular, the main clinical implementation study will be conducted at seven clinical sites across Europe, including the UK.
Impact No Impact yet
Start Year 2014
 
Description U-PGx Collaboration (Richard Turner) 
Organisation Leiden University Medical Center
Country Netherlands, Kingdom of the 
Sector Multiple 
PI Contribution Ubiquitous pharmacogenomics (U-PGx) is a large project approved by the EU Horizon 2020 Societal Challenges funding stream. Professor Sir Munir Pirmohamed and I are the UK Lead Investigators for this consortium. I have been involved since the project planning stage and assisted in the writing and reviewing of the grant application prior to acceptance. The project officially started on 1st January 2016 and I attended the Leiden kick-off meeting. We are involved in several work packages. Most importantly, the consortium will undertake a large prospective pharmacogenetics implementation study involving 8000 patients from January 2017; I am a co-investigator for the UK study site (1500 patients to be recruited) and have been heavily involved in the protocol development (work package 4). In addition, I have been involved in appointing a new pharmacist PhD fellow to the project, surveying the current knowledge and attitudes of UK clinicians regarding pharmacogenomics, selecting the genotype panel for the implementation study, and choosing the preferred 'easy-to-interpret' language that will be adopted into the genetic report for each patient (based on existing guidelines).
Collaborator Contribution The other partners of this consortium were involved in the grant application process and are now involved in delivering the project. In particular, the main clinical implementation study will be conducted at seven clinical sites across Europe, including the UK.
Impact No Impact yet
Start Year 2014
 
Description U-PGx Collaboration (Richard Turner) 
Organisation Medical University of Vienna
Country Austria, Republic of 
Sector Academic/University 
PI Contribution Ubiquitous pharmacogenomics (U-PGx) is a large project approved by the EU Horizon 2020 Societal Challenges funding stream. Professor Sir Munir Pirmohamed and I are the UK Lead Investigators for this consortium. I have been involved since the project planning stage and assisted in the writing and reviewing of the grant application prior to acceptance. The project officially started on 1st January 2016 and I attended the Leiden kick-off meeting. We are involved in several work packages. Most importantly, the consortium will undertake a large prospective pharmacogenetics implementation study involving 8000 patients from January 2017; I am a co-investigator for the UK study site (1500 patients to be recruited) and have been heavily involved in the protocol development (work package 4). In addition, I have been involved in appointing a new pharmacist PhD fellow to the project, surveying the current knowledge and attitudes of UK clinicians regarding pharmacogenomics, selecting the genotype panel for the implementation study, and choosing the preferred 'easy-to-interpret' language that will be adopted into the genetic report for each patient (based on existing guidelines).
Collaborator Contribution The other partners of this consortium were involved in the grant application process and are now involved in delivering the project. In particular, the main clinical implementation study will be conducted at seven clinical sites across Europe, including the UK.
Impact No Impact yet
Start Year 2014
 
Description U-PGx Collaboration (Richard Turner) 
Organisation Oncological Referral Centre (Centro di Riferimento Oncologico)
Country Italy, Italian Republic 
Sector Hospitals 
PI Contribution Ubiquitous pharmacogenomics (U-PGx) is a large project approved by the EU Horizon 2020 Societal Challenges funding stream. Professor Sir Munir Pirmohamed and I are the UK Lead Investigators for this consortium. I have been involved since the project planning stage and assisted in the writing and reviewing of the grant application prior to acceptance. The project officially started on 1st January 2016 and I attended the Leiden kick-off meeting. We are involved in several work packages. Most importantly, the consortium will undertake a large prospective pharmacogenetics implementation study involving 8000 patients from January 2017; I am a co-investigator for the UK study site (1500 patients to be recruited) and have been heavily involved in the protocol development (work package 4). In addition, I have been involved in appointing a new pharmacist PhD fellow to the project, surveying the current knowledge and attitudes of UK clinicians regarding pharmacogenomics, selecting the genotype panel for the implementation study, and choosing the preferred 'easy-to-interpret' language that will be adopted into the genetic report for each patient (based on existing guidelines).
Collaborator Contribution The other partners of this consortium were involved in the grant application process and are now involved in delivering the project. In particular, the main clinical implementation study will be conducted at seven clinical sites across Europe, including the UK.
Impact No Impact yet
Start Year 2014
 
Description U-PGx Collaboration (Richard Turner) 
Organisation Paul Sabatier University (University of Toulouse III)
Country France, French Republic 
Sector Academic/University 
PI Contribution Ubiquitous pharmacogenomics (U-PGx) is a large project approved by the EU Horizon 2020 Societal Challenges funding stream. Professor Sir Munir Pirmohamed and I are the UK Lead Investigators for this consortium. I have been involved since the project planning stage and assisted in the writing and reviewing of the grant application prior to acceptance. The project officially started on 1st January 2016 and I attended the Leiden kick-off meeting. We are involved in several work packages. Most importantly, the consortium will undertake a large prospective pharmacogenetics implementation study involving 8000 patients from January 2017; I am a co-investigator for the UK study site (1500 patients to be recruited) and have been heavily involved in the protocol development (work package 4). In addition, I have been involved in appointing a new pharmacist PhD fellow to the project, surveying the current knowledge and attitudes of UK clinicians regarding pharmacogenomics, selecting the genotype panel for the implementation study, and choosing the preferred 'easy-to-interpret' language that will be adopted into the genetic report for each patient (based on existing guidelines).
Collaborator Contribution The other partners of this consortium were involved in the grant application process and are now involved in delivering the project. In particular, the main clinical implementation study will be conducted at seven clinical sites across Europe, including the UK.
Impact No Impact yet
Start Year 2014
 
Description U-PGx Collaboration (Richard Turner) 
Organisation Robert Bosch Foundation
Department Robert Bosch Foundation for Medical Research (RBMF)
Country Germany, Federal Republic of 
Sector Charity/Non Profit 
PI Contribution Ubiquitous pharmacogenomics (U-PGx) is a large project approved by the EU Horizon 2020 Societal Challenges funding stream. Professor Sir Munir Pirmohamed and I are the UK Lead Investigators for this consortium. I have been involved since the project planning stage and assisted in the writing and reviewing of the grant application prior to acceptance. The project officially started on 1st January 2016 and I attended the Leiden kick-off meeting. We are involved in several work packages. Most importantly, the consortium will undertake a large prospective pharmacogenetics implementation study involving 8000 patients from January 2017; I am a co-investigator for the UK study site (1500 patients to be recruited) and have been heavily involved in the protocol development (work package 4). In addition, I have been involved in appointing a new pharmacist PhD fellow to the project, surveying the current knowledge and attitudes of UK clinicians regarding pharmacogenomics, selecting the genotype panel for the implementation study, and choosing the preferred 'easy-to-interpret' language that will be adopted into the genetic report for each patient (based on existing guidelines).
Collaborator Contribution The other partners of this consortium were involved in the grant application process and are now involved in delivering the project. In particular, the main clinical implementation study will be conducted at seven clinical sites across Europe, including the UK.
Impact No Impact yet
Start Year 2014
 
Description U-PGx Collaboration (Richard Turner) 
Organisation Servicio Cántabro de Salud
Country Spain, Kingdom of 
Sector Hospitals 
PI Contribution Ubiquitous pharmacogenomics (U-PGx) is a large project approved by the EU Horizon 2020 Societal Challenges funding stream. Professor Sir Munir Pirmohamed and I are the UK Lead Investigators for this consortium. I have been involved since the project planning stage and assisted in the writing and reviewing of the grant application prior to acceptance. The project officially started on 1st January 2016 and I attended the Leiden kick-off meeting. We are involved in several work packages. Most importantly, the consortium will undertake a large prospective pharmacogenetics implementation study involving 8000 patients from January 2017; I am a co-investigator for the UK study site (1500 patients to be recruited) and have been heavily involved in the protocol development (work package 4). In addition, I have been involved in appointing a new pharmacist PhD fellow to the project, surveying the current knowledge and attitudes of UK clinicians regarding pharmacogenomics, selecting the genotype panel for the implementation study, and choosing the preferred 'easy-to-interpret' language that will be adopted into the genetic report for each patient (based on existing guidelines).
Collaborator Contribution The other partners of this consortium were involved in the grant application process and are now involved in delivering the project. In particular, the main clinical implementation study will be conducted at seven clinical sites across Europe, including the UK.
Impact No Impact yet
Start Year 2014
 
Description U-PGx Collaboration (Richard Turner) 
Organisation St Antonius Hospital
Department St. Antonius Hospital Foundation
Country Netherlands, Kingdom of the 
Sector Hospitals 
PI Contribution Ubiquitous pharmacogenomics (U-PGx) is a large project approved by the EU Horizon 2020 Societal Challenges funding stream. Professor Sir Munir Pirmohamed and I are the UK Lead Investigators for this consortium. I have been involved since the project planning stage and assisted in the writing and reviewing of the grant application prior to acceptance. The project officially started on 1st January 2016 and I attended the Leiden kick-off meeting. We are involved in several work packages. Most importantly, the consortium will undertake a large prospective pharmacogenetics implementation study involving 8000 patients from January 2017; I am a co-investigator for the UK study site (1500 patients to be recruited) and have been heavily involved in the protocol development (work package 4). In addition, I have been involved in appointing a new pharmacist PhD fellow to the project, surveying the current knowledge and attitudes of UK clinicians regarding pharmacogenomics, selecting the genotype panel for the implementation study, and choosing the preferred 'easy-to-interpret' language that will be adopted into the genetic report for each patient (based on existing guidelines).
Collaborator Contribution The other partners of this consortium were involved in the grant application process and are now involved in delivering the project. In particular, the main clinical implementation study will be conducted at seven clinical sites across Europe, including the UK.
Impact No Impact yet
Start Year 2014
 
Description U-PGx Collaboration (Richard Turner) 
Organisation The Federal Institute for Drugs and Medical Devices
Country Germany, Federal Republic of 
Sector Public 
PI Contribution Ubiquitous pharmacogenomics (U-PGx) is a large project approved by the EU Horizon 2020 Societal Challenges funding stream. Professor Sir Munir Pirmohamed and I are the UK Lead Investigators for this consortium. I have been involved since the project planning stage and assisted in the writing and reviewing of the grant application prior to acceptance. The project officially started on 1st January 2016 and I attended the Leiden kick-off meeting. We are involved in several work packages. Most importantly, the consortium will undertake a large prospective pharmacogenetics implementation study involving 8000 patients from January 2017; I am a co-investigator for the UK study site (1500 patients to be recruited) and have been heavily involved in the protocol development (work package 4). In addition, I have been involved in appointing a new pharmacist PhD fellow to the project, surveying the current knowledge and attitudes of UK clinicians regarding pharmacogenomics, selecting the genotype panel for the implementation study, and choosing the preferred 'easy-to-interpret' language that will be adopted into the genetic report for each patient (based on existing guidelines).
Collaborator Contribution The other partners of this consortium were involved in the grant application process and are now involved in delivering the project. In particular, the main clinical implementation study will be conducted at seven clinical sites across Europe, including the UK.
Impact No Impact yet
Start Year 2014
 
Description U-PGx Collaboration (Richard Turner) 
Organisation The Golden Helix Foundation
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Private 
PI Contribution Ubiquitous pharmacogenomics (U-PGx) is a large project approved by the EU Horizon 2020 Societal Challenges funding stream. Professor Sir Munir Pirmohamed and I are the UK Lead Investigators for this consortium. I have been involved since the project planning stage and assisted in the writing and reviewing of the grant application prior to acceptance. The project officially started on 1st January 2016 and I attended the Leiden kick-off meeting. We are involved in several work packages. Most importantly, the consortium will undertake a large prospective pharmacogenetics implementation study involving 8000 patients from January 2017; I am a co-investigator for the UK study site (1500 patients to be recruited) and have been heavily involved in the protocol development (work package 4). In addition, I have been involved in appointing a new pharmacist PhD fellow to the project, surveying the current knowledge and attitudes of UK clinicians regarding pharmacogenomics, selecting the genotype panel for the implementation study, and choosing the preferred 'easy-to-interpret' language that will be adopted into the genetic report for each patient (based on existing guidelines).
Collaborator Contribution The other partners of this consortium were involved in the grant application process and are now involved in delivering the project. In particular, the main clinical implementation study will be conducted at seven clinical sites across Europe, including the UK.
Impact No Impact yet
Start Year 2014
 
Description U-PGx Collaboration (Richard Turner) 
Organisation University of Ljubljana
Country Slovenia, Republic of 
Sector Academic/University 
PI Contribution Ubiquitous pharmacogenomics (U-PGx) is a large project approved by the EU Horizon 2020 Societal Challenges funding stream. Professor Sir Munir Pirmohamed and I are the UK Lead Investigators for this consortium. I have been involved since the project planning stage and assisted in the writing and reviewing of the grant application prior to acceptance. The project officially started on 1st January 2016 and I attended the Leiden kick-off meeting. We are involved in several work packages. Most importantly, the consortium will undertake a large prospective pharmacogenetics implementation study involving 8000 patients from January 2017; I am a co-investigator for the UK study site (1500 patients to be recruited) and have been heavily involved in the protocol development (work package 4). In addition, I have been involved in appointing a new pharmacist PhD fellow to the project, surveying the current knowledge and attitudes of UK clinicians regarding pharmacogenomics, selecting the genotype panel for the implementation study, and choosing the preferred 'easy-to-interpret' language that will be adopted into the genetic report for each patient (based on existing guidelines).
Collaborator Contribution The other partners of this consortium were involved in the grant application process and are now involved in delivering the project. In particular, the main clinical implementation study will be conducted at seven clinical sites across Europe, including the UK.
Impact No Impact yet
Start Year 2014
 
Description U-PGx Collaboration (Richard Turner) 
Organisation University of Patras
Country Greece, Hellenic Republic 
Sector Academic/University 
PI Contribution Ubiquitous pharmacogenomics (U-PGx) is a large project approved by the EU Horizon 2020 Societal Challenges funding stream. Professor Sir Munir Pirmohamed and I are the UK Lead Investigators for this consortium. I have been involved since the project planning stage and assisted in the writing and reviewing of the grant application prior to acceptance. The project officially started on 1st January 2016 and I attended the Leiden kick-off meeting. We are involved in several work packages. Most importantly, the consortium will undertake a large prospective pharmacogenetics implementation study involving 8000 patients from January 2017; I am a co-investigator for the UK study site (1500 patients to be recruited) and have been heavily involved in the protocol development (work package 4). In addition, I have been involved in appointing a new pharmacist PhD fellow to the project, surveying the current knowledge and attitudes of UK clinicians regarding pharmacogenomics, selecting the genotype panel for the implementation study, and choosing the preferred 'easy-to-interpret' language that will be adopted into the genetic report for each patient (based on existing guidelines).
Collaborator Contribution The other partners of this consortium were involved in the grant application process and are now involved in delivering the project. In particular, the main clinical implementation study will be conducted at seven clinical sites across Europe, including the UK.
Impact No Impact yet
Start Year 2014
 
Description U-PGx Collaboration (Richard Turner) 
Organisation Uppsala University
Country Sweden, Kingdom of 
Sector Academic/University 
PI Contribution Ubiquitous pharmacogenomics (U-PGx) is a large project approved by the EU Horizon 2020 Societal Challenges funding stream. Professor Sir Munir Pirmohamed and I are the UK Lead Investigators for this consortium. I have been involved since the project planning stage and assisted in the writing and reviewing of the grant application prior to acceptance. The project officially started on 1st January 2016 and I attended the Leiden kick-off meeting. We are involved in several work packages. Most importantly, the consortium will undertake a large prospective pharmacogenetics implementation study involving 8000 patients from January 2017; I am a co-investigator for the UK study site (1500 patients to be recruited) and have been heavily involved in the protocol development (work package 4). In addition, I have been involved in appointing a new pharmacist PhD fellow to the project, surveying the current knowledge and attitudes of UK clinicians regarding pharmacogenomics, selecting the genotype panel for the implementation study, and choosing the preferred 'easy-to-interpret' language that will be adopted into the genetic report for each patient (based on existing guidelines).
Collaborator Contribution The other partners of this consortium were involved in the grant application process and are now involved in delivering the project. In particular, the main clinical implementation study will be conducted at seven clinical sites across Europe, including the UK.
Impact No Impact yet
Start Year 2014
 
Description UCB Pharma Pilocarpine animal epilepsy model study (Lauren Walker) 
Organisation UCB Pharma
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Private 
PI Contribution UCB will follow the protocol designed by Lauren Walker to collect brain tissue (half for western blotting and half for IHC) and serum at time points 12 weeks after pilocarpine induced status epilepticus.
Collaborator Contribution A collaboration has been established with Rafal Kaminski at UCB Pharma to undertake brain and blood sample collection from their established validated pilocarpine murine epilepsy model. UCB will meet the costs of this study.
Impact Samples have been analysed and results will be incorporated in a scientific paper (in preparation.)
Start Year 2013
 
Description University College London Hospital (Sam Nightingale) 
Organisation University College London Hospitals NHS Foundation Trust
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Public 
PI Contribution Participants in a multi site study lead by Dr Sam Nightingale (Clinical Fellow) who has attended for Site Initiation Visit and provides ongoing support to the clinical team : A) CNS Penetration of Antiretrovirals
Collaborator Contribution 15 patients were recruited to Study A of PARTITION.
Impact 15 patients were recruited to Study A of PARTITION. Analysis of samples is ongoing.
Start Year 2012
 
Description University of Manchester Bioinformatics Group (Amy Foulkes) 
Organisation University of Manchester
Department Bioinformatics
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Academic/University 
PI Contribution Patient samples collected by Amy Foulkes for her Fellowship research
Collaborator Contribution All laboratory work was paid for by the partner. Amy Foulkes worked with them in the processing of clinical samples. Future collaboration planned
Impact Currently discussing preliminary data, likely for combination publication
Start Year 2011
 
Description University of Washington (Sarah Skeoch) 
Organisation University of Washington
Department Vascular Imaging Laboratory, Department of Radiology
Country United States of America 
Sector Academic/University 
PI Contribution We are working with the team at UW on a clinical study using carotid MRI techniques which they developed. We hope to build on existing protocols to improve some imaging sequences and analysis techniques in conjunction with their team and are conducting the clinical study. The UW team have provided their imaging protocols, expertise and are training myself up to analysis the MRI scans.
Collaborator Contribution We are working with the team at UW on a clinical study using carotid MRI techniques which they developed. We hope to build on existing protocols to improve some imaging sequences and analysis techniques in conjunction with their team and are conducting the clinical study. The UW team have provided their imaging protocols, expertise and are training myself up to analysis the MRI scans.
Impact No outputs yet
Start Year 2011
 
Description Wellcome Trust CRF (Sarah Skeoch) 
Organisation Wellcome Trust
Department Wellcome Trust Clinical Research Facility
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Academic/University 
PI Contribution We applied to use the CRF for clinical visits during the research study.
Collaborator Contribution The CRF provide administrative and nursing support in addition to ultrasonography and laboratory services.
Impact None yet
Start Year 2012
 
Description Western General Hospital (Edinburgh) (Sam Nightingale) 
Organisation NHS Lothian
Country United Kingdom of Great Britain & Northern Ireland (UK) 
Sector Public 
PI Contribution Participant in two multi-site studies lead by Dr Sam Nightingale (Clinical Fellow) who has attended for Site Initiation Visit and provides ongoing support to the clinical team : 1) CNS Penetration of Antiretrovirals 2) The CNS as a sanctuary site for HIV
Collaborator Contribution 6 patients were recruited to Study A of PARTITION and 4 patients were recruited to study B of PARTITION.
Impact 6 patients were recruited to Study A of PARTITION and 4 patients were recruited to study B of PARTITION. Analysis of samples is ongoing.
Start Year 2012
 
Title PROteKT Trial 
Description PROteKT is a Phase IIa randomised, controlled trial of Rosuvastatin for the prevention of aminoglycoside-induced Kidney Toxicity in children with cystic fibrosis. It is an example of drug repurposing: utilising a licenced medication for a different indication. It is hoped that this intervention will lead to benefits for children with cystic fibrosis, and to other patients receiving aminoglycoside antibiotics. This is the first human study of rosuvastatin for this indication. The trial received funding from the JP Moulton Foundation, and is currently close to completion of recruitment. 
Type Therapeutic Intervention - Drug
Current Stage Of Development Early clinical assessment
Year Development Stage Completed 2014
Development Status Under active development/distribution
Impact This trial required a suitable, sensitive biomarker of aminoglycoside-induced kidney injury. Current clinical practice relies on change in serum creatinine which is an insensitive marker of early kidney toxicity. Through observational studies we identified a urine biomarker, kidney injury molecule-1, as a promising early marker of aminoglycoside-induced kidney toxicity. Developing and validating this biomarker has allowed us to use this as the primary outcome measure in this study. 
URL http://www.protekt-trial.org.uk/
 
Description CAP-UK Presentation (Sam Nightingale) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact 30 people from CAP-UK (a group of HIV patients who form a network of treatement advocates) attended to hear Dr Nightingale give a presentation of his research.

Dr Nightingale has been asked to train a patient representative for HIV for the Encephalitis Society.
Year(s) Of Engagement Activity 2011
 
Description 'Meet the Scientists', Liverpool World Museum, January 2016 (Richard Turner/Programme Coordinator) 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Public/other audiences
Results and Impact A group of approx 20 PhD Students and Postdoc researchers from the Centre for Drug Safety Science and the Wolfson Centre for Personalised Medicine, including Richard Turner from the Fellowship Scheme took part in this large public engagement activity which was a callobration between the Faculty of Health and Life Science at the University of Liverpool and the Liverpool World Museum in the city centre. They hosted five activity stand exploring the development of evidence based medicine and new innovations in genetics, big data and bioinformatics that will contribute to the development of personalised medicine. This was done through a series of simple table top activities aimed at children which provided students and postdocs with the opportunity to talk to adults about personalised medicine, clinical trials, drug safety as well as talking about their own research. The vent was very popular with over 500 people visiting the five stands that were under the banner 'Marvellous Medicine'. Angela Foxcroft, the Fellowship Programme Coordinator and Kerrie McGiveron, the CDSS Research Administrator played a key role in organising this event. Richard Turner (MRC Fellow) developed the activity explaining 'Clinical Trials' and ran the stand for the whole day.
Year(s) Of Engagement Activity 2016
URL https://www.liverpool.ac.uk/health-and-life-sciences/meet-the-scientists/
 
Description 'Pharmacogenomics in cardiovascular medicine,' given as a core component of the Genomics England Master's in Genomic Medicine course (Richard Myles Turner) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Postgraduate students
Results and Impact This was a teaching lecture given to students (post-graduates and healthcare professionals) taking the Genomics England MSc MDSC214 course. The lecture sparked further questions, discussion, and positive feedback. The talk provided publicity for the department's on-going work.
Year(s) Of Engagement Activity 2017
URL https://www.genomicseducation.hee.nhs.uk/taught-courses/courses/masters-in-genomic-medicine/
 
Description 'Skin Research' Newsletter (Amy Foulkes) 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Participants in your research and patient groups
Results and Impact An article about her PhD research by Amy Foulkes appeared in the November 2011 edition of a regular newsletter, 'Skin research', published by the University of Manchester and the Salford Royal Foundation Trust aimed at dermatology patients and the general public.

Continued engagement with patient group.
Year(s) Of Engagement Activity 2011
 
Description 'Ubiquitous Pharmacogenomics,' given to the North Locality Liverpool Clinical Commissioning Group (Richard Myles Turner) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Professional Practitioners
Results and Impact Purpose: to improve understanding of others thinking. The oral presentation was given to general practitioners (GPs) and provided an overview of pharmacogenomics and an introduction to the prospective pharmacogenomics clinical implementation study (PREPARE) that is commencing locally. Asked to give two more talks at other Clinical Commissioning Group (CCG) meetings.
Year(s) Of Engagement Activity 2017
 
Description 'Warfarin Pharmacogenomics,' given at the 1st Ubiquitous Pharmacogenomics Medicine Day in Granada, Spain (Richard Myles Turner) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact The oral presentation gave an overview of anticoagulant pharmacogenomics, and stimulated interest and discussion. The talk provided publicity for the department's ongoing work.
Year(s) Of Engagement Activity 2016
URL http://www.goldenhelix.org/index.php/education/golden-helix-conferences/pharmacogenomics-days/previo...
 
Description 12th European Congress on Epileptology - Novel predictive biomarkers of epileptogenesis and therapy response: bedside to bench-and back (Lauren Walker) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Lauren Walker was invited to give a platform presentation in a forum on biomarkers in epilepsy .
Year(s) Of Engagement Activity 2016
 
Description 18th Annual Resistance and Antiviral Therapy Meeting, Royal College of Physicians, London. September 2014 (Sam Nightingale) 
Form Of Engagement Activity Scientific meeting (conference/symposium etc.)
Part Of Official Scheme? No
Type Of Presentation paper presentation
Geographic Reach National
Primary Audience Other academic audiences (collaborators, peers etc.)
Results and Impact Sam Nightingale gave a talk entitled 'The CNS has an HIV reservoir (the PARTITION study)' to scientific peers during session 3 of the 18th Annual Resistance and Antiviral Therapy Meeting, Royal College of Physicians, London. September 2014

Dissemination of PhD research.
Year(s) Of Engagement Activity 2014
 
Description 2nd Inflammation in Epilepsy Meeting on immunity and inflammation (Lauren Walker) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Lauren Walker was invited to give a platform presentation in a forum on biomarkers in epilepsy - Novel predictive biomarkers of epileptogenesis and therapy response: bedside to bench-and back.
Year(s) Of Engagement Activity 2016
 
Description 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) - 2nd poster (Tim Felton) 
Form Of Engagement Activity Scientific meeting (conference/symposium etc.)
Part Of Official Scheme? No
Type Of Presentation poster presentation
Geographic Reach International
Primary Audience Other academic audiences (collaborators, peers etc.)
Results and Impact Tim Felton presented a poster sharing his group's research work:
Box H, , Gregson L, Livermore JL, Felton TW, Whalley S, Goodwin J, McEntee L, Johnson A, Hope WW. Pharmacodynamics (PD) of Isavuconazole (ISA) For Invasive Pulmonary Aspergillosis (IPA). Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington 2014. (Poster presentation, international meeting).

Tim Felton met with conference delegates in the presentation of the poster:
Box H, , Gregson L, Livermore JL, Felton TW, Whalley S, Goodwin J, McEntee L, Johnson A, Hope WW. Pharmacodynamics (PD) of Isavuconazole (ISA) For Invasive Pulmonary Aspergillosis (IPA). Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington 2014. (Poster presentation, international meeting).
Year(s) Of Engagement Activity 2014
 
Description 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) - 3rd Poster (Tim Felton) 
Form Of Engagement Activity Scientific meeting (conference/symposium etc.)
Part Of Official Scheme? No
Type Of Presentation poster presentation
Geographic Reach International
Primary Audience Other academic audiences (collaborators, peers etc.)
Results and Impact Tim Felton Presented a poster about his research work:
Ramos-Martín V, Paulus S, Siner S, Scott E, Padmore K, Newland P, Drew RJ, Felton TW, Docobo- Pérez F, Pizer B, Pea F, Peak M, Turner MA, Beresford MW, Hope WW. Population Pharmacokinetics of Teicoplanin in Children and Neonates. Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington 2014. (Poster presentation, international meeting).

Poster presentation provided the opportunity to talk to international delegates about research work.
Ramos-Martín V, Paulus S, Siner S, Scott E, Padmore K, Newland P, Drew RJ, Felton TW, Docobo- Pérez F, Pizer B, Pea F, Peak M, Turner MA, Beresford MW, Hope WW. Population Pharmacokinetics of Teicoplanin in Children and Neonates. Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington 2014. (Poster presentation, international meeting).
Year(s) Of Engagement Activity 2014
 
Description 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 1st poster (Tim Felton) 
Form Of Engagement Activity Scientific meeting (conference/symposium etc.)
Part Of Official Scheme? No
Type Of Presentation poster presentation
Geographic Reach International
Primary Audience Other academic audiences (collaborators, peers etc.)
Results and Impact Presentation of a Poster:
Felton TW, Livermore J, Goodwin J, Sharp AD, Gregson L, Hope WW. Pharmacodynamic rationale for intermittent dosing of micafungin in immunocompetent patients. Washington 2014. (Poster presentation, international meeting).

Meeting with other Delegates to share research work:
Felton TW, Livermore J, Goodwin J, Sharp AD, Gregson L, Hope WW. Pharmacodynamic rationale for intermittent dosing of micafungin in immunocompetent patients. Washington 2014. (Poster presentation, international meeting).
Year(s) Of Engagement Activity 2014
 
Description A Clinical Pharmacology lecture for junior doctors in the Mersey region undertaking the membership of the Royal Colleges of Physicians (MRCP) examinations (2015) (Richard Myles Turner) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Professional Practitioners
Results and Impact I gave a clinical pharmacology revision lecture to junior doctors from the Mersey region to help them prepare for their MRCP examinations. The talk sparked discussion and questions.

This activity helped educate junior doctors about clinical pharmacology and provided a platform to elevate the profile of Clinical Pharmacology & Therapeutics as an attractive and important medical specialty.
Year(s) Of Engagement Activity 2015
 
Description A pharmacology lecture for physicians undertaking the membership of the Royal Colleges of Physicians (MRCP) Part I examination given on behalf of the Royal College of Physicians (2016) (Richard Myles Turner) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Professional Practitioners
Results and Impact On behalf of the Royal College of Physicians, I gave a lecture covering basic and clinical pharmacology to junior doctors to help them prepare for their MRCP Part I written examination. The talk sparked significant engagement, discussion, questions, and I believe increased their understanding of pharmacology (2016).

This activity helped educate junior doctors in pharmacology and raised awareness of the specialty of Clinical Pharmacology & Therapeutics.
Year(s) Of Engagement Activity 2016
URL https://www.rcplondon.ac.uk/events/mrcp-uk-part-1-refresher-workshop
 
Description AMS/MRS/RCP Meeting for Clinician Scientists in Training. London. February 2012 (John Reynolds) 
Form Of Engagement Activity Scientific meeting (conference/symposium etc.)
Part Of Official Scheme? No
Type Of Presentation Poster Presentation
Geographic Reach National
Primary Audience Other academic audiences (collaborators, peers etc.)
Results and Impact Poster Presentation of Research
Year(s) Of Engagement Activity 2012
 
Description AMS/MRS/RCP Meeting for Clinician Scientists in Training. London. February 2013 (John Reynolds) 
Form Of Engagement Activity Scientific meeting (conference/symposium etc.)
Part Of Official Scheme? No
Type Of Presentation Poster Presentation
Geographic Reach National
Primary Audience Other academic audiences (collaborators, peers etc.)
Results and Impact Poster Presentation of Research
Year(s) Of Engagement Activity 2013
 
Description AMS/MRS/RCP Meeting for Clinician Scientists in Training. London. March 2014 (John Reynolds) 
Form Of Engagement Activity Scientific meeting (conference/symposium etc.)
Part Of Official Scheme? No
Type Of Presentation Poster Presentation
Geographic Reach National
Primary Audience Other academic audiences (collaborators, peers etc.)
Results and Impact Poster Presentation of Research
Year(s) Of Engagement Activity 2008,2014
 
Description Academic Paediatric Association Conference (2014) (Stephen McWilliam) 
Form Of Engagement Activity Scientific meeting (conference/symposium etc.)
Part Of Official Scheme? No
Type Of Presentation Paper Presentation
Geographic Reach National
Primary Audience Other academic audiences (collaborators, peers etc.)
Results and Impact This event took place in Winchester , and was organised by the Academic Paediatric Association. There were aproximately 50 people there. The presentation was entitled: 'Association of Urinary Kidney Injury Molecule-1 with Aminoglycoside Exposure in Children with Cystic Fibrosis'

None yet
Year(s) Of Engagement Activity 2014
 
Description Academic Paediatricians in Training Meeting 2013 (James McCaffrey) 
Form Of Engagement Activity Scientific meeting (conference/symposium etc.)
Part Of Official Scheme? No
Type Of Presentation Poster Presentation
Geographic Reach National
Primary Audience Health professionals
Results and Impact Scientific meeting increasing awareness of research being performed by junior paediatricians across the country.

None yet
Year(s) Of Engagement Activity 2013
 
Description Academic poster entitled, 'The impact of P450 oxidoreductase knock out on systemic exposure to rosuvastatin, atorvastatin and atorvastatin metabolites,' presented at the British Pharmacological Society 2016 Meeting (Richard Myles Turner) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Other audiences
Results and Impact A poster presentation I presented at the British Pharmacological Society 2016 annual international meeting. The poster sparked conversations about the research presented. The talk provided publicity for my on-going research.
Year(s) Of Engagement Activity 2016
URL https://www.bps.ac.uk/pharmacology2016#Overview
 
Description Academy of Medical Science meeting (Amy Foulkes) 
Form Of Engagement Activity Scientific meeting (conference/symposium etc.)
Part Of Official Scheme? No
Type Of Presentation Keynote/Invited Speaker
Geographic Reach Regional
Primary Audience Other academic audiences (collaborators, peers etc.)
Results and Impact Amy spoke about industry collaboration at an Academy of Medical Science event in May 2012

As a result Amy Foulkes was interviewed by Kath Nightingale (MRC Press Officer) for the creation of a scientist profile for the MRC website
Year(s) Of Engagement Activity 2012
 
Description Academy of Medical Sciences 2014 (Vincent Yip) 
Form Of Engagement Activity Scientific meeting (conference/symposium etc.)
Part Of Official Scheme? No
Type Of Presentation Poster Presentation
Geographic Reach National
Primary Audience Other academic audiences (collaborators, peers etc.)
Results and Impact Vincent Yip gave a poster presentation of his MRC research work

Discussion with fellow clinical academics about research and training.
Year(s) Of Engagement Activity 2014
 
Description Academy of Medical Sciences Spring Meeting for Clinical Scientists in Training (Sarah Skeoch) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Other academic audiences (collaborators, peers etc.)
Results and Impact Poster Presentation: Evaluation of carotid plaque inflammation in patients with rheumatoid arthritis using 18F-fluorodeoxyglucose PET-MRI: a pilot study. Sarah Skeoch, Heather Williams, Penny Cristinacce, Paul Hockings, Jacqueline James, Yvonne Alexander, John Waterton, Ian Bruce.


Networking and discussion of ideas with other researchers
Year(s) Of Engagement Activity 2015
 
Description Academy of Medical Sciences meeting, Feb 2015 (Meghna Jani) 
Form Of Engagement Activity Scientific meeting (conference/symposium etc.)
Part Of Official Scheme? No
Type Of Presentation paper presentation
Geographic Reach International
Primary Audience Health professionals
Results and Impact Poster presentation sparked discussion

Disseminated findings to a clinical and research audience, to improve clinical care and impact future guidelines
Year(s) Of Engagement Activity 2014
 
Description Academy of Medical Sciences/ Royal College of Physicians - Clinician Scientists in Training Meeting (Meghna Jani) 
Form Of Engagement Activity Scientific meeting (conference/symposium etc.)
Part Of Official Scheme? No
Type Of Presentation Poster Presentation
Geographic Reach National
Primary Audience Health professionals
Results and Impact Poster presentation of research to scientific audience/Healthcare professionals.

Disseminated findings to a clinical and research audience, to improve clinical care and impact future guidelines
Year(s) Of Engagement Activity 2014
 
Description Advances against Aspergillus, 2012, Istanbul, Turkey (Tim Felton) 
Form Of Engagement Activity Scientific meeting (conference/symposium etc.)
Part Of Official Scheme? No
Type Of Presentation Poster Presentation
Geographic Reach International
Primary Audience Health professionals
Results and Impact Tim Felton was present at the posters during poster rounds.

http://www.advancesagainstaspergillosis.org/2012/index.htm

Chrdle A, Mustakim S, Bright-Thomas R, Baxter CG, Felton TW, Denning DW. Aspergillus bronchitis in non-immunocompromised patients - case series, response to treatment and criteria for diagnosis. Advances against aspergillosis. Istanbul. 2012. - POSTER PRESENTATION

Tim felton was involved in many discussions around the topic with delegates.
Year(s) Of Engagement Activity 2012
 
Description American College of Rheumatism Annual Conference (Sarah Skeoch) 
Form Of Engagement Activity Scientific meeting (conference/symposium etc.)
Part Of Official Scheme? No
Type Of Presentation Poster Presentation
Geographic Reach International
Primary Audience Other academic audiences (collaborators, peers etc.)
Results and Impact Imaging atherosclerotic plaque inflammation in RA: methodology an initial findings in a single centre cohort
S Skeoch, P. Hubbard, H. Williams, D. Xu, S. Jie, N. Balu, W. Zhang, J. James, T. Hatsukami, C. Yuan, Y. Alexander, P.Hockings, J. Waterton, I. Bruce
Presented at the American College of Rheumatism Annual Conference, San Diego, 2013

None yet.
Year(s) Of Engagement Activity 2013
 
Description American College of Rheumatology (ACR) 2013 (James Bluett 1st entry) 
Form Of Engagement Activity Scientific meeting (conference/symposium etc.)
Part Of Official Scheme? No
Type Of Presentation poster presentation
Geographic Reach International
Primary Audience Other academic audiences (collaborators, peers etc.)
Results and Impact James Bluett presented a poster entitled 'Impact of inadequate adherence on clinical outcomes: Results from the biologics in rheumatoid arthritis genetics and genomics study syndicate cohort'

None Yet
Year(s) Of Engagement Activity 2013
 
Description American College of Rheumatology (ACR) 2013 (James Bluett 2nd entry) 
Form Of Engagement Activity Scientific meeting (conference/symposium etc.)
Part Of Official Scheme? No
Type Of Presentation poster presentation
Geographic Reach International
Primary Audience Other academic audiences (collaborators, peers etc.)
Results and Impact James Bluett presented a poster, 'Investigating a novel locus for psoriatic arthritis' at an international conference.

None Yet
Year(s) Of Engagement Activity 2013
 
Description American College of Rheumatology Annual Conference, November 2015 (Meghna Jani) (1) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Scientific Oral presentation. Disseminated findings to a clinical and research audience, to improve clinical care and impact future guidelines.
Year(s) Of Engagement Activity 2015
 
Description American College of Rheumatology Annual Conference, November 2015 (Meghna Jani) (2) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Poster presentation. Disseminated findings to a clinical and research audience, to improve clinical care and impact future guidelines.
Year(s) Of Engagement Activity 2015
 
Description American College of Rheumatology Conference 2014: Boston 2014 (John Reynolds) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Other academic audiences (collaborators, peers etc.)
Results and Impact Presentation on John Reynolds' research in an oral abstract session

None yet
Year(s) Of Engagement Activity 2014
 
Description American College of Rheumatology Conference San Diego November 2013 (John Reynolds) 
Form Of Engagement Activity Scientific meeting (conference/symposium etc.)
Part Of Official Scheme? No
Type Of Presentation Poster Presentation
Geographic Reach International
Primary Audience Other academic audiences (collaborators, peers etc.)
Results and Impact Poster Presentation of Research
Year(s) Of Engagement Activity 2009,2013
 
Description American College of Rheumatology Conference Washington DC November 2012 (John Reynolds) 
Form Of Engagement Activity Scientific meeting (conference/symposium etc.)
Part Of Official Scheme? No
Type Of Presentation Poster Presentation
Geographic Reach International
Primary Audience Other academic audiences (collaborators, peers etc.)
Results and Impact Poster Presentation of Research
Year(s) Of Engagement Activity 2012
 
Description American College of Rheumatology annual Conference, Boston 2014 (Meghna Jani) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Other academic audiences (collaborators, peers etc.)
Results and Impact Scientific oral presentation

Disseminated findings to a clinical and research audience, to improve clinical care and impact future guidelines.
Year(s) Of Engagement Activity 2014
 
Description American Society of Nephrology Meeting (Atlanta)2013 (James McCaffrey) 
Form Of Engagement Activity Scientific meeting (conference/symposium etc.)
Part Of Official Scheme? No
Type Of Presentation Poster Presentation
Geographic Reach International
Primary Audience Health professionals
Results and Impact International scientific meeting involveing discussion of James McCaffrey's poster with interested participants.

None yet.
Year(s) Of Engagement Activity 2013
 
Description An oral lecture for University of Liverpool year 2 medical students entitled, 'Biologics and Biosimilars' (2016) (Richard Myles Turner) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Undergraduate students
Results and Impact I gave a lecture to year 2 medical students on behalf of the Clinical Pharmacology department as part of delivering the new University of Liverpool undergraduate medical curriculum (2016).

This activity helped educate undergraduate medical students about the development and pharmacology of biologics and biosimilars.
Year(s) Of Engagement Activity 2008,2016
 
Description An oral lecture for University of Liverpool year 3 medical students entitled, 'Cardiac Arrhythmias & Antiarrhythmics (2015) (Richard Myles Turner) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Undergraduate students
Results and Impact Richard Turner gave a lecture to year 3 medical students as part of the Clinical Pharmacology curriculum (2015). This activity helped educate undergraduate medical students about arrhythmia pharmacology.
Year(s) Of Engagement Activity 2015
 
Description Association for Science Education 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? Yes
Type Of Presentation Keynote/Invited Speaker
Geographic Reach National
Primary Audience Schools
Results and Impact 30 science teachers attended to hear of latest developments in personalised medicine

asked to go and present in shools
Year(s) Of Engagement Activity 2012
 
Description BAD meeting (Amy Foulkes) 
Form Of Engagement Activity Scientific meeting (conference/symposium etc.)
Part Of Official Scheme? No
Type Of Presentation Poster Presentation
Geographic Reach National
Primary Audience Other academic audiences (collaborators, peers etc.)
Results and Impact British Association of Dermatologists meeting 2012 Poster presentation 'Patient satisfaction in a specialist combined dermatology and rheumatology clinic'

None
Year(s) Of Engagement Activity 2012
 
Description BPS The Future of Drugs Event at the Dana Centre at the Science Museum in London (Vincent Yip) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact Presentation to the public about personalised medicines: past, present and future. Part of biology week and organised by the British Pharmacological Society

None yet
Year(s) Of Engagement Activity 2014
 
Description BPS Winter Meeting - 2017 (Vincent Yip) 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Other audiences
Results and Impact Oral Presentation of latest findings from PhD research
Year(s) Of Engagement Activity 2017
 
Description BPS Winter Meeting Dec 2015 (Vincent Yip) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Poster presentation of latest findings from PhD research
Year(s) Of Engagement Activity 2015
 
Description BSR Annual Conference (Sarah Skeoch) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Type Of Presentation paper presentation
Geographic Reach National
Primary Audience Schools
Results and Impact Poster Tour presentation "Investigation of the prevalence and phenotype of atherosclerosis in patients with rheumatoid arthritis"
S. Skeoch, P. Cristinacce, H. Williams, D. Xu, S. Jie, N. Balu, J. James, C. Yuan, T. Hatsukami, P. Hockings, Y. Alexander, J. Waterton, I. Bruce.


None yet
Year(s) Of Engagement Activity 2015
 
Description Body Experience, Manchester Museum (James McCaffrey) 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? Yes
Type Of Presentation Workshop Facilitator
Geographic Reach Regional
Primary Audience Public/other audiences
Results and Impact James McCaffrey explained how the kidney functions and what his project involves

Increased awareness of local population to research activities ongoing at University of Manchester
Year(s) Of Engagement Activity 2014
 
Description Brain Awareness Week (Dr Sam Nightingale) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Type Of Presentation Workshop Facilitator
Geographic Reach Regional
Primary Audience Public/other audiences
Results and Impact Dr Sam Nightingale arranged 5 public events with stalls and activities to engage the public. Approximately 300 members of the public attended these events. A competition for children gained 30 entries

The events reached the attention of the media. Sam Nightingale was interviewed on local radio which allowed my message to reach a wider audience.
Year(s) Of Engagement Activity 2012
 
Description British Pharmacological Society Annual Meeting (Dec 2013) (Vincent Yip) 
Form Of Engagement Activity Scientific meeting (conference/symposium etc.)
Part Of Official Scheme? No
Type Of Presentation Paper Presentation
Geographic Reach International
Primary Audience Other academic audiences (collaborators, peers etc.)
Results and Impact Vincent Yip presented an overview of his MRC research

None Yet
Year(s) Of Engagement Activity 2013
 
Description British Pharmacological Society Conference - Poster Presentation (2013) (Stephen McWilliam) 
Form Of Engagement Activity Scientific meeting (conference/symposium etc.)
Part Of Official Scheme? No
Type Of Presentation Poster Presentation
Geographic Reach National
Primary Audience Other academic audiences (collaborators, peers etc.)
Results and Impact Poster presentation at British Pharmacological Society Conference entitled 'Reference Intervals For Urinary Kidney Injury Molecule-1 And Neutrophil Gelatinase-Associated Lipocalin In Children'.

None yet
Year(s) Of Engagement Activity 2013
 
Description British Pharmacological Society Winter Meeting Dec 2013 (Lauren Walker) 
Form Of Engagement Activity Scientific meeting (conference/symposium etc.)
Part Of Official Scheme? No
Type Of Presentation Poster Presentation
Geographic Reach National
Primary Audience Other academic audiences (collaborators, peers etc.)
Results and Impact Lauren Walker submitted and abstract and gave a poster presentation of research results to date

None Yet
Year(s) Of Engagement Activity 2013
 
Description British Pharmacological Society annual flagship meeting (2015) (Richard Turner) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact This was a presentation, entitled 'Investigating the prevalence, predictors and prognosis of suboptimal statin therapy early after a non-ST elevation acute coronary syndrome' concerning the the research Richard Turner has been conducting as part of his Fellowship on the North West England MRC Scheme in Clinical Pharmacology & Therapeutics. The presentation was well received and led to a thought-provoking discussion.

Richard was awarded the GlaxoSmithKline Prize for clinical oral communications as a result of this presentation at the British Pharmacological Society flagship annual meeting.
Year(s) Of Engagement Activity 2015
URL https://www.bps.ac.uk/news-events/future-scientific-meetings/2015/pharmacology-2015#
 
Description British Society For Rheumatology Annual Conference (Meghna Jani) 
Form Of Engagement Activity Scientific meeting (conference/symposium etc.)
Part Of Official Scheme? No
Type Of Presentation Poster Presentation
Geographic Reach National
Primary Audience Health professionals
Results and Impact Poster presentation of research to scientific audience/Healthcare professionals.

Disseminated findings to a clinical and research audience, to improve clinical care and impact future guidelines
Year(s) Of Engagement Activity 2014
 
Description British Society for Rheumatology Conference Birmingham April 2013 (John Reynolds) 
Form Of Engagement Activity Scientific meeting (conference/symposium etc.)
Part Of Official Scheme? No
Type Of Presentation Poster Presentation
Geographic Reach National
Primary Audience Other academic audiences (collaborators, peers etc.)
Results and Impact Poster Presentation of Research
Year(s) Of Engagement Activity 2013
 
Description British Society for Rheumatology Conference Glasgow April 2012 (John Reynolds) 
Form Of Engagement Activity Scientific meeting (conference/symposium etc.)
Part Of Official Scheme? No
Type Of Presentation Poster Presentation
Geographic Reach National
Primary Audience Other academic audiences (collaborators, peers etc.)
Results and Impact Poster Presentation of Research
Year(s) Of Engagement Activity 2012
 
Description British Society for Rheumatology Conference Glasgow April 2016 (John Reynolds) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Other audiences
Results and Impact Poster Presentation of Research
Year(s) Of Engagement Activity 2016
 
Description British Society for Rheumatology meeting, April 2015 (Meghna Jani) 
Form Of Engagement Activity Scientific meeting (conference/symposium etc.)
Part Of Official Scheme? No
Type Of Presentation paper presentation
Geographic Reach National
Primary Audience Health professionals
Results and Impact Disseminated findings to a clinical and research audience, to improve patient safety and impact future guidelines

None Yet
Year(s) Of Engagement Activity 2015
 
Description British Society for Rheumatology meeting, April 2015 (Meghna Jani) 
Form Of Engagement Activity Scientific meeting (conference/symposium etc.)
Part Of Official Scheme? No
Type Of Presentation paper presentation
Geographic Reach National
Primary Audience Health professionals
Results and Impact Scientific oral presentation X1

Disseminated findings to a clinical and research audience, to improve clinical care and impact future guidelines
Year(s) Of Engagement Activity 2015
 
Description British Society of Rheumatology (BSR) 2013 (James Bluett 1st entry) 
Form Of Engagement Activity Scientific meeting (conference/symposium etc.)
Part Of Official Scheme? No
Type Of Presentation poster presentation
Geographic Reach National
Primary Audience Other academic audiences (collaborators, peers etc.)
Results and Impact James Bluett presented a poster entitled, 'Using encode data to identify potential functional genetic variants at the 5q31 psoriatic arthritis susceptibility locus'

None Yet
Year(s) Of Engagement Activity 2013
 
Description British Society of Rheumatology (BSR) 2014 (James Bluett) 
Form Of Engagement Activity Scientific meeting (conference/symposium etc.)
Part Of Official Scheme? No
Type Of Presentation poster presentation
Geographic Reach National
Primary Audience Other academic audiences (collaborators, peers etc.)
Results and Impact Poster presentation 'North west regional audit: Management of polymyalgia rheumatica' at a national conference. North west regional audit: Management of polymyalgia rheumatica

None yet
Year(s) Of Engagement Activity 2014
 
Description British Thoracic Society Winter Meeting. 2015. (Time Felton) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Poster presentation: Survival in patients with chronic type 2 respiratory failure: a comparison of obesity hypoventilation syndrome, COPD and overlap syndrome. ( Jothieswaran A, Mascareno M, Bokhari S, Chaudhry N, Felton TW, Bentley AM)
Year(s) Of Engagement Activity 2015
 
Description British Transplant Association/Renal association conference 2013 (James McCaffrey) 
Form Of Engagement Activity Scientific meeting (conference/symposium etc.)
Part Of Official Scheme? No
Type Of Presentation Poster Presentation
Geographic Reach National
Primary Audience Health professionals
Results and Impact Scientific meeting/National conference. Moderated poster presentation consisting of 5 min talk followed by questions.

None yet
Year(s) Of Engagement Activity 2013
 
Description British society for Rheumatology Conference 2016, poster presentation (Sarah Skeoch) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Other audiences
Results and Impact Sarah Skeoch presented a regional audit on the use of PET imaging in rheumatology and the development of a regional referral pathway.
Year(s) Of Engagement Activity 2013,2016
 
Description British society for rheumatology annual conference 2013 (Meghna Jani) 
Form Of Engagement Activity Scientific meeting (conference/symposium etc.)
Part Of Official Scheme? No
Type Of Presentation Paper Presentation
Geographic Reach National
Primary Audience Health professionals
Results and Impact Scientific oral presentation.
Disseminated findings to a clinical and research audience, to improve clinical care and impact future guidelines


Disseminated findings to a clinical and research audience, to improve clinical care and impact future guidelines
Year(s) Of Engagement Activity 2013
 
Description CSF/plasma HIV-1 RNA discordance, even at low level is associated with up -regulation of host inflammatory mediators in cerebrospinal fluid 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Platform presentation to physicians and allied health professional at British HIV Association conference.
Year(s) Of Engagement Activity 2015
 
Description Cheltenham Science Festival 7th July 2014 (BPS PERSONALISED MEDICINE ) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? Yes
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact Present a broad range of science and scientific issues in an exciting and engaging environment.

To present a broad range of science and scientific issues in an exciting and engaging environment t encourge people to pursue careers in science and bring to life
Year(s) Of Engagement Activity 2014
 
Description Community Open day- Arthritis Research UK stand (6th July 2013) (Meghna Jani) 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? No
Type Of Presentation Workshop Facilitator
Geographic Reach Local
Primary Audience Public/other audiences
Results and Impact 6 Arthritis research UK researchers took part in this event. Meghna Jani conducted joint ultrasound on willing participants and explained how this may impact on research in Rheumatology.

The activity was popular with children and adults. Many were curious and inquisitive about the techniques used and were interested in exploring more about the imaging modality and musculoskeletal research.
Year(s) Of Engagement Activity 2013
 
Description Community Open day- Faculty of Medicine and Human Sciences (28th June 2014) (Meghna Jani) 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Type Of Presentation Paper Presentation
Geographic Reach Regional
Primary Audience Public/other audiences
Results and Impact Use of ultrasound in musculoskeletal research

Disseminated findings to a clinical and research audience, to improve clinical care and impact future guidelines
Year(s) Of Engagement Activity 2014
 
Description Conference for Retrovirology and Opportunistic infection (CROI) 2014, Boston Massachusetts (Sam Nightingale) 
Form Of Engagement Activity Scientific meeting (conference/symposium etc.)
Part Of Official Scheme? No
Type Of Presentation Paper Presentation
Geographic Reach International
Primary Audience Other academic audiences (collaborators, peers etc.)
Results and Impact Sam Nightingale presented his research data at an international conference - Conference for Retrovirology and Opportunistic infection. Nightingale S, on behalf of the PARTITION investigators. HIV-1 RNA Detection in CSF in ART Treated Subjects with Incomplete Viral Suppression in Plasma.

This is the major US HIV conference. Sam Nightingale spoke to approx 600 people. He met leaders in the field and discussed potential collaborations.
Year(s) Of Engagement Activity 2014
URL http://www.croi2014.org/
 
Description Conference on Retroviruses & Opportunistic Infections, Seattle, Mar 5-9, 2012 
Form Of Engagement Activity Scientific meeting (conference/symposium etc.)
Part Of Official Scheme? No
Type Of Presentation Poster Presentation
Geographic Reach International
Primary Audience Other academic audiences (collaborators, peers etc.)
Results and Impact Presented the study background for TAILoR at this International HIV conference.

Presentation was well appreciated
Year(s) Of Engagement Activity 2010,2012
URL http://www.retroviruses.org
 
Description Conference: Health is Wealth (Dr Anna Olsson-Brown) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact To share information. Stimulated panel debate within the session.
Year(s) Of Engagement Activity 2017
URL http://www.liverpoollep.org/events/health-wealth-2017-conference/
 
Description Contributed article to "Young Persons' University blog" (James McCaffrey) 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Schools
Results and Impact This Blog has been developed for secondary school and college students and is used to showcase research that PhD students are doing at the Univeristy of Manchester.
James McCaffrey Explained in lay-terms the basis of his PhD research question

Increased awareness of local population to research activities ongoing at University of Manchester, and encouraging young people to apply for University and post-graduate education.
Year(s) Of Engagement Activity 2014
URL http://www.ypu.manchester.ac.uk/blog/pondering-podocytes
 
Description Digestive Diseases Week (Richard Kia) 
Form Of Engagement Activity Scientific meeting (conference/symposium etc.)
Part Of Official Scheme? No
Type Of Presentation Paper Presentation
Geographic Reach International
Primary Audience Other academic audiences (collaborators, peers etc.)
Results and Impact Oral presentation of research at the annual premier gastroenterology conference DDW entitled, " Phenotypic Comparison of Hepatocyte-Like Cells Differentiated From Human Induced Pluripotent Stem Cells Derived by Cellular Reprogramming of Primary Hepatocytes and Dermal Fibroblasts Obtained From the Same Donor" organised jointly by a few societies including American Association for the Study of Liver Diseases, in Chicago, May 5, 2014.

Publicity of research and dissemination of preliminary findings
Year(s) Of Engagement Activity 2014
 
Description Donders Neuroscience Discussion (Oct 2013) (Vincent Yip) 
Form Of Engagement Activity Scientific meeting (conference/symposium etc.)
Part Of Official Scheme? No
Type Of Presentation Keynote/Invited Speaker
Geographic Reach International
Primary Audience Postgraduate students
Results and Impact Vincent Yip presented an overview of pharmacogenetics in neurology and his own MRC funded research project to other PhD students from a variety of neuroscience, neuropsychiatry and international backgrounds.

Non yet.
Year(s) Of Engagement Activity 2013
URL http://www.ru.nl/dondersdiscussions/about/about_the_donders/
 
Description EACPT Summer School (July 2013) (Vincent Yip) 
Form Of Engagement Activity Scientific meeting (conference/symposium etc.)
Part Of Official Scheme? No
Type Of Presentation Poster Presentation
Geographic Reach National
Primary Audience Other academic audiences (collaborators, peers etc.)
Results and Impact Vincent Yip gave a poster presentation of his MRC research work

Discussion with fellow clinical academics about research and training.
Year(s) Of Engagement Activity 2013
 
Description EACPT Summer School Edinburgh July 2013 (Lauren Walker) 
Form Of Engagement Activity Scientific meeting (conference/symposium etc.)
Part Of Official Scheme? No
Type Of Presentation Poster Presentation
Geographic Reach National
Primary Audience Other academic audiences (collaborators, peers etc.)
Results and Impact Lauren Walker submitted and abstract and gave a poster presentation of research results to date.

None yet.
Year(s) Of Engagement Activity 2013
 
Description EULAR Congress 2013 (2) (Sarah Skeoch) 
Form Of Engagement Activity Scientific meeting (conference/symposium etc.)
Part Of Official Scheme? No
Type Of Presentation Poster Presentation
Geographic Reach International
Primary Audience Other academic audiences (collaborators, peers etc.)
Results and Impact Poster presentation: Antibody positivity is associated with increased arterial stiffness in rheumatoid arthritis patients: results from the Norfolk Arthritis Register
S. Skeoch, S. Verstappen, J. Chipping, T. Marshall, D.P. Symmons, I.Bruce
Presented at the EULAR congress, Madrid 2013

None yet
Year(s) Of Engagement Activity 2013
 
Description EULAR annual Conference, Paris 2014 (Meghna Jani) 
Form Of Engagement Activity Scientific meeting (conference/symposium etc.)
Part Of Official Scheme? No
Type Of Presentation Paper Presentation
Geographic Reach International
Primary Audience Other academic audiences (collaborators, peers etc.)
Results and Impact Scientific oral presentation

Disseminated findings to a clinical and research audience, to improve clinical care and impact future guidelines
Year(s) Of Engagement Activity 2014
 
Description EULAR annual conference 2013 (Meghna Jani) 
Form Of Engagement Activity Scientific meeting (conference/symposium etc.)
Part Of Official Scheme? No
Type Of Presentation Poster Presentation
Geographic Reach International
Primary Audience Health professionals
Results and Impact Poster presentation of research to scientific audience/Healthcare professionals.

Disseminated findings to a clinical and research audience, to improve clinical care and impact future guidelines
Year(s) Of Engagement Activity 2013
 
Description EULAR annual conference 2014 (2) (Meghna Jani) 
Form Of Engagement Activity Scientific meeting (conference/symposium etc.)
Part Of Official Scheme? No
Type Of Presentation Poster Presentation
Geographic Reach International
Primary Audience Health professionals
Results and Impact Poster presentation of research to scientific audience/Healthcare professionals.

Disseminated findings to a clinical and research audience, to improve clinical care and impact future guidelines
Year(s) Of Engagement Activity 2014
 
Description EULAR annual conference, June 2015 (Meghna Jani) 
Form Of Engagement Activity Scientific meeting (conference/symposium etc.)
Part Of Official Scheme? No
Type Of Presentation paper presentation
Geographic Reach National
Primary Audience Health professionals
Results and Impact Poster presentations X2

Disseminated findings to a clinical and research audience, to improve clinical care and impact future guidelines
Year(s) Of Engagement Activity 2015
 
Description EULAR congress 2013 (Sarah Skeoch) 
Form Of Engagement Activity Scientific meeting (conference/symposium etc.)
Part Of Official Scheme? No
Type Of Presentation Paper Presentation
Geographic Reach International
Primary Audience Other academic audiences (collaborators, peers etc.)
Results and Impact Oral Presentation: Assessment of lupus nephritis disease activity using non-contrast MRI: A pilot study.
S.Skeoch, M.Dobbs, P.Hubbard, J. Naish, N.Woodhouse, M. Ho, J.Waterton, G. Parker, I. Bruce.

Paper presented at the EULAR congress, Madrid, 2013

Currently writing a paper and meeting to discuss a collaberation for a larger study.
Year(s) Of Engagement Activity 2013
 
Description Encephalitis Society fact sheet (Sam Nightingale) 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact Dr Nightingale wrote a patient fact-sheet on HIV cognitive impairment that has been published on encephalitis society website and linked to the Terrence Higgins Trust Website

none
Year(s) Of Engagement Activity 2011
 
Description European Congress of Clinical Microbiology and Infectious Diseases, 2012, London, UK (Tim Felton) 
Form Of Engagement Activity Scientific meeting (conference/symposium etc.)
Part Of Official Scheme? No
Type Of Presentation Poster Presentation
Geographic Reach International
Primary Audience Health professionals
Results and Impact Tim Felton was present at the posters during poster rounds.

http://www.congrex.ch/eccmid2012/home.html

Felton TW, Roberts S, Brennan S, Philips A, Whiteside A, Doran H, Leonard C, Al-Aloul M, Isalska B, Yonan N, Hope WW. Isolation of Aspergillus species from the respiratory tract of lung transplant recipients is associated with increased mortality. ECCMID. London 2012. - POSTER PRESENTATION

Tim took part in discussion with many delagates about the topic.
Year(s) Of Engagement Activity 2012
 
Description European Cystic Fibrosis Society Conference - Poster Presentation (2014) (Stephen McWilliam) 
Form Of Engagement Activity Scientific meeting (conference/symposium etc.)
Part Of Official Scheme? No
Type Of Presentation Poster Presentation
Geographic Reach International
Primary Audience Other academic audiences (collaborators, peers etc.)
Results and Impact Poster and oral presentation at European Cystic Fibrosis Society Conference entitled 'Association of Urinary Kidney Injury Molecule-1 with Aminoglycoside Exposure in Children with Cystic Fibrosis'.

None yet
Year(s) Of Engagement Activity 2014
 
Description European Immunogenicity Platform, Lisbon Feb 2014 (Meghna Jani) 
Form Of Engagement Activity Scientific meeting (conference/symposium etc.)
Part Of Official Scheme? No
Type Of Presentation Paper Presentation
Geographic Reach International
Primary Audience Health professionals
Results and Impact Oral- Invited speaker - The effect of DMARDs on immunogenicity of anti-TNF agents

New research contacts, publicity of work
Year(s) Of Engagement Activity 2014
 
Description European Society of Paediatric Infectious Diseases conference (Dublin 2014) (Tim Felton) 
Form Of Engagement Activity Scientific meeting (conference/symposium etc.)
Part Of Official Scheme? No
Type Of Presentation poster presentation
Geographic Reach International
Primary Audience Other academic audiences (collaborators, peers etc.)
Results and Impact Tim Felton presented a poster:
Ramos-Martín V, Paulus S, Siner S, Scott E, Padmore K, Newland P, Drew RJ, Felton TW, Docobo- Pérez F, Pizer B, Pea F, Peak M, Turner MA, Beresford MW, Hope WW. LIPSTIC: Liverpool pharmacokinetic study of teicoplanin in children. European Society of Paediatric Infectious Diseases. Dublin 2014. (Poster presentation, international meeting).

The poster presentation provided an opportunity for Tim Felton to meet with conference delegates and talk about his work:
Ramos-Martín V, Paulus S, Siner S, Scott E, Padmore K, Newland P, Drew RJ, Felton TW, Docobo- Pérez F, Pizer B, Pea F, Peak M, Turner MA, Beresford MW, Hope WW. LIPSTIC: Liverpool pharmacokinetic study of teicoplanin in children. European Society of Paediatric Infectious Diseases. Dublin 2014. (Poster presentation, international meeting).
Year(s) Of Engagement Activity 2014
 
Description European Society of Paediatric Nephrology Meeting 2015 (James McCaffrey) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Health professionals
Results and Impact Oral presentation at a scientific meeting. Main attendees were paediatric nephrologists from across Europe.

None yet
Year(s) Of Engagement Activity 2015
 
Description Expert Opinion on BBC Radio Warwickshire Radio Breakfast show 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Public/other audiences
Results and Impact University Press office was approached by the BBC seeking an expert opinion on the dangers of buying prescription medication via the internet (Namely Roacutane). Vincent Yip was appraoched as a dermato-pharmacologist and agreed to take part in a telephone interview to explain the danger of buying and using this drug with correct medical supervision.

Raised publi awareness regarding the dangers of obtaining prescription only medications through the internet.
Year(s) Of Engagement Activity 2015
 
Description Expression of Unique and Diverse HIV Variants in Cerebrospinal Fluid during ART 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Poster presentation to physicians and allied health professional at Conference for retrovirology and Opportunistic infections (CROI).
Year(s) Of Engagement Activity 2017
 
Description GMANN Winter Symposium 2014 (James McCaffrey) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Health professionals
Results and Impact Oral presentation at scientific meeting regarding my research on this Fellowship. Main attendees were nephrologists from the North West. Triggered discussion about best ways to develop targeted therapeutics for treatment of proteinuric disease.

None yet
Year(s) Of Engagement Activity 2014
URL http://s3.extravision.com/gmann/news-and-events/2014/101214-agenda.pdf
 
Description HMGB1 World Congress, October 2013 New York City Feinstein Institute (Lauren Walker) 
Form Of Engagement Activity Scientific meeting (conference/symposium etc.)
Part Of Official Scheme? No
Type Of Presentation Poster Presentation
Geographic Reach International
Primary Audience Other academic audiences (collaborators, peers etc.)
Results and Impact Lauren Walker submitted an abstract (For publication in Mol Med journal) and gave a poster presentation on research results to date. Also named as a co-author and collaborator in the platform presentation of results on the development of a Meso Scale Discovery assay for detection of HMGB1.

None Yet
Year(s) Of Engagement Activity 2013
 
Description Immunoconvention, Berlin (31st October- 1st November 2014) (Meghna Jani) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Other academic audiences (collaborators, peers etc.)
Results and Impact Talks: (1) Using treatment algorithms in inflammatory disease (rheumatology) (2) Clinical relevance of immunogenicity- case studies from daily practice: rheumatology

Invited speaker for 2 talks as outlined above. Each talk 30-45 minutes followed by workshop/discussion.
Possible new collaboration
Year(s) Of Engagement Activity 2014
 
Description Interactive school assembly presentation (Stephen McWilliam) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Type Of Presentation Keynote/Invited Speaker
Geographic Reach Local
Primary Audience Schools
Results and Impact The activity formed part of school's participation in a research study. - Around 200 children attended the assembly (in two groups). The children participated in the assembly by answering questions and voting. A large number of children asked questions at the end of the assembly.

No formal assessment of impact. Lot's of children (and parents) agreed to be healthy volunteers for study and provided urine samples.
Year(s) Of Engagement Activity 2012
 
Description International League Against Epilepsy UK Chapter Meeting, Glasgow September 2013 (Lauren Walker) 
Form Of Engagement Activity Scientific meeting (conference/symposium etc.)
Part Of Official Scheme? No
Type Of Presentation Poster Presentation
Geographic Reach National
Primary Audience Other academic audiences (collaborators, peers etc.)
Results and Impact Lauren Walker submitted an abstract and gave a poster presentation of research results to date.

None yet
Year(s) Of Engagement Activity 2013
 
Description International Society for Antimicrobial Pharmacology, 2012, San Francisco, USA (Tim Felton) 
Form Of Engagement Activity Scientific meeting (conference/symposium etc.)
Part Of Official Scheme? No
Type Of Presentation Paper Presentation
Geographic Reach International
Primary Audience Health professionals
Results and Impact Tim Felton gave a presentation to a large auditorium of doctors/scientist with an interest in this area.

http://www.isap.org/

Felton TW, Livermore J, Goodwin J, Sharp A, Gregson L, , Howard S, Warn P, Hope WW. Impact Of Intermittent Dosing Of Micafungin In Neutropenic And Non-Neutropenic Patients Using A Translation Pharmacology Approach. International Society for Antimicrobial Pharmacology. San Francisco 2012 -SPOKEN PRESENTATION

Interesting discussion after the presentation and after the session which has led to potential collaborations.
Year(s) Of Engagement Activity 2012
 
Description Interscience Conference on Antimicrobial Agents and Chemotherapy, 2012, San Francisco, USA (Tim Felton) 
Form Of Engagement Activity Scientific meeting (conference/symposium etc.)
Part Of Official Scheme? No
Type Of Presentation Paper Presentation
Geographic Reach International
Primary Audience Health professionals
Results and Impact Presentation to a large auditorium of doctors/scientist with an interest in this area.

http://www.icaac.org/

•Felton TW, O'Connor L, Goodwin J, Sharp A, Gregson L, Livermore J, Howard S, Hope WW. Impact of Administration of Piperacillin-Tazobactam by Extended Infusion on Emergence of Resistance in an In Vitro Hollow Fiber Infection Model (HFIM). ICAAC. San Francisco 2012. - SPOKEN PRESENTATION

•Livermore JL, Sharp A, Walker C, Moser W, Gregson L, Goodwin J, Felton TW, Howard SJ, Mueller W, Perfect J, Hope WW. The Antifungal Activity of an Abbreviated Regimen of Amphotericin B Deoxycholate (DAmB) For Cryptococcal Meningitis is Due to Persistence of Drug in the Brain Rather Than T-Cell Recruitment. ICAAC. San Francisco 2012. - POSTER PRESENTATION

•O'Connor L, Livermore J, Sharp A, Goodwin J, Felton TW, Howard SJ, Hope WW. Pharmacokinetics (PK) and Pharmacodynamics (PD) of Liposomal Amphotericin B (LAmB) and Flucytosine (5FC) against Cryptococcus neoformans in a Murine Model of Cryptococcal Meningitis. ICAAC. San Francisco 2012. - POSTER PRESENTATION

•Sudan A, Livermore J, Howard S, Al-Nakeeb Z, Sharp A, Goodwin J, Gregson L, Wilkinson T, Warn PA, Felton TW, Hope WW. Pharmacokinetics and Pharmacodynamics of Fluconazole in a Murine Model of Cryptococcal Meningitis With Bridging to Humans: High Dosages are Required for Near-Maximal Antifungal Activity. ICAAC. San Francisco 2012. - POSTER PRESENTATION

•Livermore J, O'Connor L, Sharp A, Gregson L, Goodwin J, Warn PA, Felton TW, Schwartz JA, Howard SJ, Hope WW. Pharmacokinetics and Pharmacodynamics of Liposomal Amphotericin B (LAmB) for Cryptococcal Meningitis: A Single High Dose of Liposomal Amphotericin B is as Efficacious as Daily Dosing Regimens. ICAAC. San Francisco 2012. - POSTER PRESENTATION


Interesting discussion after the presentation and after the session which has led to potential collaborations.
Year(s) Of Engagement Activity 2012
 
Description Interscience Conference on Antimicrobial Agents and Chemotherapy. Denver 2013. (Poster presentation) (Tim Felton) 
Form Of Engagement Activity Scientific meeting (conference/symposium etc.)
Part Of Official Scheme? No
Type Of Presentation Poster Presentation
Geographic Reach International
Primary Audience Health professionals
Results and Impact Felton TW, Roberts JA, Lodise TP, Boselli E, Van Guilder M, Neely M, Hope WW. Software for Dosage Individualisation of Piperacillin/Tazobactam for critically ill patients. Interscience Conference on Antimicrobial Agents and Chemotherapy. Denver 2013. (Poster presentation, international meeting).
Year(s) Of Engagement Activity 2013
 
Description Interscience Conference on Antimicrobial Agents and Chemotherapy. Denver 2013. (Tim Felton) 
Form Of Engagement Activity Scientific meeting (conference/symposium etc.)
Part Of Official Scheme? No
Type Of Presentation Keynote/Invited Speaker
Geographic Reach International
Primary Audience Health professionals
Results and Impact Presentation to a large auditorium of doctors/scientist with an interest in this area. Felton TW. Continuous infusions of Beta-Lactams. Interscience Conference on Antimicrobial Agents and Chemotherapy. Denver 2013. (Invited speaker)

Interesting discussion after the presentation and after the session which has led to potential collaborations.
Year(s) Of Engagement Activity 2013
URL http://www.icaac.org/
 
Description Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego 2015 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Poster presentation: 16s rRNA Gene Sequencing Applied to Bronchoalveolar Lavage Fluid of Critically Ill Patients is Able to Detect Pathogens and May Influence Antibiotic Therapy. (Thomas S, Logan JMJ, Hassan I, Barker J, Ashworth A, Barnes A, Feddy L, Hayes T, Malagon I, Stirling S, Szentgyorgi L, Chand MA, Mutton K, Felton TW)
Year(s) Of Engagement Activity 2015
 
Description Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego 2015 (Tim Felton) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Poster Presentation: Piperacillin Time Above MIC Correlates with Improved Outcomes (O'Donnell JN, Rhodes NJ, Day JZ, Jett RS, Felton TW, Neely MN, Scheetz MH)
Year(s) Of Engagement Activity 2015
 
Description Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego 2015 (invitied speaker) (Tim Felton) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Tim Felton, Invited Speaker to conference. Gave a presentation entitled, "Clinical Pharmacokinetics/Pharmacodynamics (PK/PD) of the Lung"
Year(s) Of Engagement Activity 2015
 
Description Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego 2015(Invited speaker 2) (Tim Felton) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Tim Felton was invited to give a presentaiton at this conference, "Application of Pharmacokinetic/Pharmacodynamic (PK/PD) Models"
Year(s) Of Engagement Activity 2015
 
Description Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego 2015. (Poster presentation, international meeting). 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Poster Presentation: Model-based Prediction of Piperacillin Concentrations in Critically Ill Patients: A Comparison of Nine Approaches Against Clinical Data. (Farkas A, Gujadhur N, Yasin B, Felton TW, Roberts J)
Year(s) Of Engagement Activity 2015
 
Description Interviewed for online profile (Amy Foulkes) 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Type Of Presentation Keynote/Invited Speaker
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact Amy foulkes was interviewed by Kath Nightingale (MRC Press Officer) for the creation of a scientist profile for the MRC website.
http://www.mrc.ac.uk/Achievementsimpact/Profiles/AmyFoulkes/index.htm

No impact yet.
Year(s) Of Engagement Activity 2012
 
Description Joint Drug Metabolism Discussion Group and Groupe de Metabolisme et Pharmacocinetique Meeting 2014 (Vincent Yip) 
Form Of Engagement Activity Scientific meeting (conference/symposium etc.)
Part Of Official Scheme? No
Type Of Presentation poster presentation
Geographic Reach International
Primary Audience Other academic audiences (collaborators, peers etc.)
Results and Impact Vincent Yip gave a poster presentation of his MRC research work

Discussion with fellow clinical academics and industry regarding current work and future work.
Year(s) Of Engagement Activity 2014
 
Description Junior café Sci, Withington Girls School (Sarah Skeoch) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Type Of Presentation Keynote/Invited Speaker
Geographic Reach Local
Primary Audience Schools
Results and Impact Sarah Skeoch gave a brief talk then an extended question and answer session to a group of secondary school children about a career in medical research at their junior café Sci meeting.

Positive feedback was given by both teachers and pupils
Year(s) Of Engagement Activity 2013
 
Description Laboratory attachment by A Level students (July 2013) (Richard Kia) 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Schools
Results and Impact Ricahrd Kia supervised an A Level student who was thinking of a career in science in general and also the possibility of doing research during/after her undergraduate degree. She was exposed to what research involves and also discussed about the rigours of careers in medicine and clinical pharmacology.

None yet
Year(s) Of Engagement Activity 2013
 
Description Laboratory attachment by an undergraduate student (July 2013) (Ricahrd Kia) 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Undergraduate students
Results and Impact Ricahrd Kia supervised an undergraduate pharmacology student who obtained a British Pharmacology Society Summer Studentship for his attachment to the MRC CDSS. He was exposed to our research focus of assessing the utility of human-derived stem cells as a tool for drug screening.

None yet
Year(s) Of Engagement Activity 2013
 
Description Life Sciences Careers Conference (Royal Society of Biology) (Oct 2015) (Vincent Yip) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Undergraduate students
Results and Impact Provide undergraduates with advice regarding careers choices and life as a clinical academic
Year(s) Of Engagement Activity 2015
URL http://lscc.rsb.org.uk/
 
Description Liverpool-Malawi-Wellcome Conference 2013 (Sam Nightingale) 
Form Of Engagement Activity Scientific meeting (conference/symposium etc.)
Part Of Official Scheme? No
Type Of Presentation Paper Presentation
Geographic Reach International
Primary Audience Health professionals
Results and Impact Sam Nightingale presented his research data at an international conference - The Liverpool-Malawi Wellcome Conference, Blantyre, Malawi.

Sam Nightingale spoke to approx 200 people. The presentation sparked interesting dicussions. Potential for future Collaborations for work in a similar area in the developing world.
Year(s) Of Engagement Activity 2013
 
Description Lupus 2013: International Congress on Systemic Lupus Erythematosus: Argentina 2013 (John Reynolds) 
Form Of Engagement Activity Scientific meeting (conference/symposium etc.)
Part Of Official Scheme? No
Type Of Presentation Paper Presentation
Geographic Reach International
Primary Audience Other academic audiences (collaborators, peers etc.)
Results and Impact Presentation on John Reynolds' research in an oral abstract session

This has resulted in early discussions of collaboration between the University of Manchester and a research group in the US.
Year(s) Of Engagement Activity 2013
 
Description Lupus Open Evening (as part of Lupus Awareness Month 2013) (John Reynolds) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? Yes
Type Of Presentation Keynote/Invited Speaker
Geographic Reach Regional
Primary Audience Public/other audiences
Results and Impact Patients and their family members attended the open evening to learn about current lupus research. John Reynolds presented the results of my research.

None yet
Year(s) Of Engagement Activity 2014
 
Description Lupus Open Evening (as part of Lupus Awareness Month) (John Reynolds) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Type Of Presentation Keynote/Invited Speaker
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact Around 60 patients and their family members attended the open evening to learn about current lupus research. There was a discussion afterwards in which many attendees participated. The event received excellent feedback

This resulted in a number of patients contacting their physician or myself asking to take part in the research project.
Year(s) Of Engagement Activity 2011
 
Description Lupus UK North West AGM (John Reynolds) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Public/other audiences
Results and Impact Patients and their family members attended regional AGM. 3 external speakers were invited to present clinical talks or their research. I presented results from the research undertaken as part of the MRC scheme.
Year(s) Of Engagement Activity 2016
 
Description MRC CDSS International Workshop (Richard Kia) 
Form Of Engagement Activity Scientific meeting (conference/symposium etc.)
Part Of Official Scheme? No
Type Of Presentation Poster Presentation
Geographic Reach International
Primary Audience Other academic audiences (collaborators, peers etc.)
Results and Impact Poster presented at International Workshop entitled, "In vitro endpoints and markers of hepatotoxicity" organised by MRC CDSS at the University of Liverpool on 17 September 2013

None yet.
Year(s) Of Engagement Activity 2013
 
Description MRC Centenary Celebrations (Vincent Yip) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Type Of Presentation Keynote/Invited Speaker
Geographic Reach Local
Primary Audience Public/other audiences
Results and Impact Vincent Yip gave a 20 minute presentation about personalised medicines. How personalised medicines are used today, their benefits and how they will be incorporated into future healthcare. Brief overview of MRC CPT fellowship.

The activity was very popular with members of the local council, prospective students and the general public attending. Stimulating discussion during coffee with members of the audience.
Year(s) Of Engagement Activity 2013
 
Description MRC Centenary Showcase Presentation (Vincent Yip) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Type Of Presentation Keynote/Invited Speaker
Geographic Reach Regional
Primary Audience Public/other audiences
Results and Impact MRC Centenary Showcase Presentation to patients and public. Overview of personalised medicine and applications in the future as part of the University of Liverpool's contribution to the MRC's Centenary celebrations.

None yet
Year(s) Of Engagement Activity 2013
 
Description Manchester Science Fair - Psoriasis Exhibition (Amy Foulkes) 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Public/other audiences
Results and Impact This was a well publicised, well attended event.

None
Year(s) Of Engagement Activity 2011
 
Description Manchester Science Spectacular 2013 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? Yes
Geographic Reach Regional
Primary Audience Public/other audiences
Results and Impact The North West England Fellowship Scheme hosted a stand at the Manchester Science Spectacular called 'Marvellouse Medicine', which introudcued children and their families to drugs and where they come from and to the idea of personalised medicine.

Approximately 80 children took part in the activities and the group received spontaneous positive feedback from several parents.
Year(s) Of Engagement Activity 2013
 
Description Manchester Science Spectacular 2014 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Public/other audiences
Results and Impact MRC Fellows, Academic Clinical Fellows and members of the British Pharmacology Society hosted an acticity stand, called 'My Marvellouse Medicine' at this event which attracts over 1000 members of the general public every year. Approximately 100 children and their families took part in the activities on the stand which sought to educate children and their parents about personalised medicine, stratification, drug trials and medicine production.

Feedback from paretns was extremely positive and children enjoyed the activities.
Year(s) Of Engagement Activity 2014
URL http://www.engagement.manchester.ac.uk/highlights/manchester_science_festival/science_spectacular/
 
Description Manchester Science Spectacular 2015 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Public/other audiences
Results and Impact The Manchester Science Spectacular runs annually and is an opportunity for scientists to showcase their research work to an audience of children and families. The event is attended by approximately 1,500 people.

Interactive table top activity aimed at families and children to teach about medicine and where it comes from as well as personalised health. Several MRC Fellows took part in the event. Approximately 100 children took part in this activity.


This is the fourth year MRC Fellows have taken part in this event and the stand Marvellous Medicine has become a regular acticity stand at this event.
Year(s) Of Engagement Activity 2015
 
Description Meet the Scientists faculty public engagement event (2016) (Richard Myles Turner) 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Public/other audiences
Results and Impact I was involved in a 'meet the scientists' public engagement day hosted by the faculty. Specifically, I was involved in the design and running of a stand that provided interactive games to help understand clinical trial methodology, the placebo-effect, and randomization.

This activity helped educate members of the public about clinical trials, the efficacy and safety of therapeutics, the potential of personalised medicine, and the associated ongoing research being conducted at the University of Liverpool.
Year(s) Of Engagement Activity 2016
URL https://www.liverpool.ac.uk/health-and-life-sciences/meet-the-scientists/
 
Description NIHR Media competition entry "Imaging inflammation in rheumatoid arthritis" (Sarah Skeoch) 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact Sarah Skeoch entred into the NIHR media competition in March 2013 which comprised of a filmed discussion with a patient about why we were conducting research into vascular inflammation in RA that now appears on youtube.

The film has been viewed over 400 times on youtube.
Year(s) Of Engagement Activity 2013
URL https://www.youtube.com/watch?v=ik4NdFtV64U
 
Description NIHR Visit to the NIHR/Wellcome Trust Clinical Research Facility 29/4/2013 (John Reynolds) 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? No
Type Of Presentation Workshop Facilitator
Geographic Reach National
Primary Audience Supporters
Results and Impact A formal visit by senior members of the NIHR to observe the infrastructure and facilities at the NIHR Wellcome Trust clinical research facility. John demonstrated the equipment that he is using as part of his study and discussed the support network within the facility.

Demonstration of my work to senior members of the NIHR.
Year(s) Of Engagement Activity 2013
 
Description NOWGEN: A Level Visit (Sarah Skeoch) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Type Of Presentation Workshop Facilitator
Geographic Reach Local
Primary Audience Schools
Results and Impact Sarah Skeoch arranged a session for A level students visiting the University of Manchester at the NIHR/Wellcome Trust Clinical Research Facility. The session included discussion and demonstrations of musculoskeletal imaging (MRI and ultrasound)

Positive feedback was received and further "meet the scientist " days are being planned for January 2014
Year(s) Of Engagement Activity 2013
 
Description NOWGEN: A-Level Visit Day 25/1/13 (John Reynolds) 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? No
Type Of Presentation Workshop Facilitator
Geographic Reach Local
Primary Audience Schools
Results and Impact Around 50 A-level students attended NOWGEN at the NIHR Wellcome Trust Clinical Research facility in Manchester. Students attended in small groups to receive demonstrations of current research techniques. This was to encourage an interest in pursuing science beyond A-level.

Students gave good feedback and took an active part in the demonstrations and discussions.
Year(s) Of Engagement Activity 2013
 
Description NWE MRC Annual Showcase 2012 (All MRC CPT Research Fellows) 
Form Of Engagement Activity Scientific meeting (conference/symposium etc.)
Part Of Official Scheme? No
Type Of Presentation Paper Presentation
Geographic Reach National
Primary Audience Other academic audiences (collaborators, peers etc.)
Results and Impact 11 Clinical Research Fellows presented their ongoing MRC Research to an audience of approximately 50 academic and industry peers in Liverpool. Presentations were also made by Prof. Peter Clayton, University of Manchester and Dr Chris Chamberlain, Astra Zeneca.

An opportunity for MRC Research Fellows to network and learn more about developing research careers.
Year(s) Of Engagement Activity 2012
 
Description NWE MRC Fellowship Annual Showcase 2011 (All MRC CPT Research Fellows) 
Form Of Engagement Activity Scientific meeting (conference/symposium etc.)
Part Of Official Scheme? No
Type Of Presentation Paper Presentation
Geographic Reach National
Primary Audience Other academic audiences (collaborators, peers etc.)
Results and Impact 8 MRC Clinical research Fellows presented their research to an audience of approx 50 academic and industry peers alongside a number of external speakers (Prof Martin Wilkins, UCL and Prof Caroline Savage, Head of Discovery Medicine at GSK) in Liverpool.

An opportunity for Clinical Research Fellows on the North West England Scheme in Clinical Pharmacology and Therapeutics to network.
Year(s) Of Engagement Activity 2011
 
Description National Nephrotic Syndrome patient information day (James McCaffrey) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact Talk improved understanding of Nephrotic syndrome among sufferers.
Year(s) Of Engagement Activity 2016
URL https://research.cmft.nhs.uk/news-events/manchester-event-for-patients-with-nephrotic-syndrome-and-t...
 
Description National Paediatric Clinical Pharmacology Workshop Presentation (2013) (Stephen McWilliam) 
Form Of Engagement Activity Scientific meeting (conference/symposium etc.)
Part Of Official Scheme? No
Type Of Presentation Paper Presentation
Geographic Reach National
Primary Audience Other academic audiences (collaborators, peers etc.)
Results and Impact This event took place at the Royal Derby Hospital, and was organised by Professor Imti Choonara who is a Paediatric Clinical Pharmacologist. There were probably around 30 people there.

Non yet
Year(s) Of Engagement Activity 2013
 
Description Neuro-Infections Charities Network presentation (Sam Nightingale) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact 80 multidisciplinary professionals who work with people who have neurological infection and patients who have recovered from such infections that now offer help and support to sufferers.

none
Year(s) Of Engagement Activity 2011
 
Description North West Clinical Academic Training Annual Meeting Oct 2012 (Amy Foulkes) 
Form Of Engagement Activity Scientific meeting (conference/symposium etc.)
Part Of Official Scheme? No
Type Of Presentation Keynote/Invited Speaker
Geographic Reach Local
Primary Audience Other academic audiences (collaborators, peers etc.)
Results and Impact North West Clinical Academic Training Annual Meeting Oct 2012 Talk on early research collaboration with industry

None
Year(s) Of Engagement Activity 2012
 
Description North West Coast Academic Health Science Network Atrial Fibrillation Symposium Day (Richard Myles Turner) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Professional Practitioners
Results and Impact Richard Turner gave an oral presentation entitled, 'Genotype-Guided Warfarin Dosing' regarding the current state-of-the art of warfarin pharmacogenomics in the context of Personalised Medicine at the North West Coast Academic Health and Science Network Atrial Fibrillation symposium day. This sparked subsequent discussion with requests for copies of the presentation slides and led to a separate meeting with Dr Tom Dawson, founder of Rescon Technologies (a mobile healthcare technology private enterprise). This may lead to a new collaboration.
Presentation available on YouTube: https://www.youtube.com/watch?v=MvEKkd8FV74
Year(s) Of Engagement Activity 2015
URL https://www.eventbrite.co.uk/e/innovation-in-identifying-and-managing-atrial-fibrillation-symposium-...
 
Description North of England Dermatology Society Meeting (Amy Foulkes) 
Form Of Engagement Activity Scientific meeting (conference/symposium etc.)
Part Of Official Scheme? No
Type Of Presentation Poster Presentation
Geographic Reach Regional
Primary Audience Other academic audiences (collaborators, peers etc.)
Results and Impact North of England Dermatological Society March 2012 Poster presentation

None
Year(s) Of Engagement Activity 2012
 
Description Organisation of Seminar from External Speakers - Sengenics (Dr Anna Olsson-Brown; Dr Neil French) 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Postgraduate students
Results and Impact To share information. Stimulated debate and questions within the attendees.
Year(s) Of Engagement Activity 2017
 
Description Paediatric Intensive Care Society 2013 (James McCaffrey) 
Form Of Engagement Activity Scientific meeting (conference/symposium etc.)
Part Of Official Scheme? No
Type Of Presentation Poster Presentation
Geographic Reach National
Primary Audience Health professionals
Results and Impact National Conference/Scientific meeting

Discussion helped refine data analysis of acute kidney injury (AKI) biomarker trial we have run in the paediatric intensive care unit (PICU) at the Royal Manchester Children's Hospital (RMCH). This article has been submitted for review for publication on 16 June 2014. This trial has contributed to one of the biomarkers in the project becoming routinely available for RMCH PICU patients.
Year(s) Of Engagement Activity 2013
 
Description Pan-Manchester Academic Nephrology Meeting 2012 (James McCaffrey) 
Form Of Engagement Activity Scientific meeting (conference/symposium etc.)
Part Of Official Scheme? No
Type Of Presentation paper presentation
Geographic Reach Regional
Primary Audience Health professionals
Results and Impact Oral presentation at a scientific meeting. Selection of clinicians and scientists from Manchester area who are involved in renal medicine. 20 minute talk, 5 mins questions.

None yet.
Year(s) Of Engagement Activity 2012
 
Description Participant Feedback day (Sarah Skeoch) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Public/other audiences
Results and Impact Sarah Skeoch arranged a feedback day for patricipants and staff who had taken part in the research study she had conducted during my PhD fellowship. She gave a presentation and then undertook and question and answer session

Feedback from participant perspective for future studies
Year(s) Of Engagement Activity 2015
 
Description Personalised Medicine Workshop Presentation (2013) (Stephen McWilliam) 
Form Of Engagement Activity Scientific meeting (conference/symposium etc.)
Part Of Official Scheme? No
Type Of Presentation Paper Presentation
Geographic Reach Local
Primary Audience Other academic audiences (collaborators, peers etc.)
Results and Impact Presentation at a Workshop at the University of Liverpool Institute of Translational Medicine. Stephen McWilliam presented his MRC research and outcomes to date.

None yet
Year(s) Of Engagement Activity 2013
 
Description Play on Personalised Medicine 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? Yes
Type Of Presentation Keynote/Invited Speaker
Geographic Reach National
Primary Audience Schools
Results and Impact This involved a number of activities - (a) an initial workshop with 14-16 year olds and a presentation on personalised medicine to these students, and to a playwright; (b) helping the playwright to develop a play on personalised medicine; (c) commenting on the script; (d) meeting actors who acted in the play and undertaking a general Q&A session; (e) attending the play and taking part in a debate session with members of the general public. All these activities were undertaken with the Y-touring theatre company. Further details available on the website: http://www.theatreofdebate.com/Projects/Dayglo/Story.html

The play was performed in many schools throughout the UK. it also ran for 1 week at the Royal Albert Hall. A DVD of the play which is called "Dayglo" has been made and was shown at the Edinburgh Science Festival, and will also be shown to medical students initially at Liverpool and eventually nationally.
Year(s) Of Engagement Activity 2011,2012
 
Description Podocyte International Conference, Freiburg, Germany, 2014 (James McCaffrey) 
Form Of Engagement Activity Scientific meeting (conference/symposium etc.)
Part Of Official Scheme? No
Type Of Presentation Poster Presentation
Geographic Reach International
Primary Audience Health professionals
Results and Impact Discussion around poster with conference attendees

Impact Description: Discussions helped with ongoing ChIP-Seq in vitro work, and in vivo work involving rodent model of nephrotic syndrome we have developed.
Year(s) Of Engagement Activity 2014
 
Description Primary School Event, St. Mary's CE Primary School, Reddish, Stockport (James McCaffrey) 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? No
Type Of Presentation Workshop Facilitator
Geographic Reach Local
Primary Audience Schools
Results and Impact James McCaffrey explained what the kidney does to primary school children

Increased enthusiasm for science and physiology among school children
Year(s) Of Engagement Activity 2014
 
Description Psoriasis Awareness Day - Salford Royal NHS Foundation Trust (Amy Foulkes) 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Public/other audiences
Results and Impact Well publicised and well attended event.

none
Year(s) Of Engagement Activity 2011
 
Description Psoriasis and Psoriatc Arthritis Alliance Patient information leaflet Clinical trials (Amy Foulkes) 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact None yet

Patient information leaflet about clinical trials, freely available online
Year(s) Of Engagement Activity 2013
URL http://www.papaa.org/references/clinical-trials-overview
 
Description Research mobility and drug discovery workshop attendance (2015) (Richard Myles Turner) 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact The Researcher mobility in drug discovery two-day workshop flagship event of the Royal Society of Chemistry, co-organised by the British Pharmacological Society and the Biochemical Society.
Richard Turner attended this two-day residential workshop brought together researchers from across the life sciences spectrum (clinical, chemistry, biology) and from both academic and industry backgrounds, and aimed to helped engender a stronger desire for closer working ties and collaboration between disciplines and sectors, in order to improve productivity.
Richard has joined a LinkedIn forum made up of delegates at this workshop, and I hope that this will prove a useful resource for future collaborative research initiatives.
Year(s) Of Engagement Activity 2015
URL https://www.bps.ac.uk/news-events/future-scientific-meetings/2015/researcher-mobility-in-drug-discov...
 
Description Rheumatology 2015: British Society of Rheumatology Conference : Manchester 2015 (John Reynolds) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Other academic audiences (collaborators, peers etc.)
Results and Impact Presentation on John Reynolds' research in an oral abstract session

None yet
Year(s) Of Engagement Activity 2015
 
Description Royal College of Physicians Careers Fayre London October 2013 (Lauren Walker) 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Type Of Presentation Workshop Facilitator
Geographic Reach National
Primary Audience Undergraduate students
Results and Impact Supported by the BPS, Lauren Walker attended the careers fayre at the Royal College of physicians in order to promote Clinical Pharmacology and careers in academic medicine. Approximately 500 people attended the all-day event.

Lauren Walker spoke to many medical students about fellowships and career pathways in academic medicine.
Year(s) Of Engagement Activity 2013
 
Description Royal Liverpool University Hospital medical Grand Round (2015) (Richard Myles Turner) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Professional Practitioners
Results and Impact Richard Turner gave an oral presentation entitled 'Warfarin Pharmacogenetics', as part of a programme of presentations given at a Royal Liverpool University Hospital medical Grand Round. The aim was to highlight to clinicians the current research into personalised medicine being carried out at the Wolfson Centre for Personalised Medicine (University of Liverpool). The talks helped to engender interest in the subject and we received positive feedback about the usefulness of the event.
This activity helped educate clinicians about the current research base for personalised medicine and brought to their attention the ongoing initiatives to implement pharmacogenetic testing into specific clinics at the Royal Liverpool hospital.
Year(s) Of Engagement Activity 2016
 
Description Royal Manchester Children's Hospital Grand Round (James McCaffrey) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Professional Practitioners
Results and Impact Talk resulted in discussion about how best to detect Acute Kidney Injury (AKI) in patients at Royal Manchester Children's Hospital (RMCH). This talk showcased work from our AKI biomarker paper..one of the biomarkers in this trial is now in routine use at RMCH.
Year(s) Of Engagement Activity 2013
 
Description STEM Ambassador Training (Sarah Skeoch) 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? Yes
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact Sarah Skeoch attended the Science Technology, Engineering and Mathematics Ambassador training programme which aims to promote and explain STEM subjects to children of all ages. She is now a member of the STEM network and school visits have been arranged in forthcoming months.

Ongoing promotion of STEM subjects.
Year(s) Of Engagement Activity 2013
URL http://www.stemnet.org.uk/
 
Description School careers presentation (Stephen McWilliam) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Type Of Presentation Keynote/Invited Speaker
Geographic Reach Local
Primary Audience Schools
Results and Impact Around 100 Year 12 students attended the presentation They participated by answering questions. A number asked questions at the end of the presentation.

No formal assessment of impact
Year(s) Of Engagement Activity 2012
 
Description Science Festival (Manchester) (Several NWE MRC CPT Research Fellows) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Type Of Presentation Workshop Facilitator
Geographic Reach Regional
Primary Audience Public/other audiences
Results and Impact 9 NWE MRC Fellows ran a table top activity entitled 'Marvellouse Medicine' at the University of Manchester Science Spectacular event (Part of the Manchester Science Festival). Approximately 2000 people visited the event with approximately 75 children (under 10) and their families taking part in the activity.

The activity was popular with visitors and the research Fellows are keen to take part in the event again next year. Several GCSE and A Level students also spoke to the Fellows about careers in medeicine, pharmacology and scientific research.
Year(s) Of Engagement Activity 2012
 
Description Science Grrl (Sarah Skeoch) 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? Yes
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact A calendar was produced which portrays real female scientists carrying out work. One of the months was based on Sarah Skeoch's current research study and the calendars are on sale at various science museums around the country. Sarah Skeoch featured in the picture and attend a press launch to promote the calendar and cause and has on-going meetings with other members to discuss further fund raising and public engagement activities.

On-going promotion of STEM subjects to girls and young women.
Year(s) Of Engagement Activity 2012
 
Description Science to go- series for the Manchester Fellowship Academy (Meghna Jani) 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Undergraduate students
Results and Impact Meghna Jani filmed a video regarding clinical research plans and gaining external funding

To inspire younger students on the variety of research and opportunities available with the University of Manchester
Year(s) Of Engagement Activity 2013
 
Description Statin-induced muscle toxicity: evaluating the functional effects of variability in P450 oxidoreductase (2015) (Richard Myles Turner) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Other audiences
Results and Impact I gave an oral presentation at the University of Liverpool Institute of Translational Medicine Research Day covering my PhD fellowship project rationale and results to date (2015). This led to interesting and productive conversations.

This activity provided publicity for both my project and the MRC fellowship scheme that I am currently enrolled on.
Year(s) Of Engagement Activity 2015
 
Description The 21st International Reid Bioanalytical Forum (2015) Dried blood spot assay development poster presentation (Richard Myles Turner) (Richard Turner) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Richard Turner was involved in the assay development and data acquisition that was presented at this international conference by Dr Mark Bayliss within a poster entitled, 'Dried-blood spotting combined with fused core HPLC-MS/MS for the measurement of atorvastatin, simvastatin and rosuvastatin in support of PK studies in the mouse'. Authors listed are: Bayliss M, Turner R, Kitteringham N, French N, Park K, Pirmohamed M. The presentation sparked further talk regarding micro-sampling techniques, and we were informed about a potential new card material that should overcome the haematocrit limitation of current dried blood spot technologies. This activity provided publicity for our ongoing work
Year(s) Of Engagement Activity 2015
URL http://www.bmss.org.uk/Docs/BioForum%202015%20second%20circular%20FInal2-1.pdf
 
Description The European league against rheumatism (EULAR ) (James Bluett) 
Form Of Engagement Activity Scientific meeting (conference/symposium etc.)
Part Of Official Scheme? No
Type Of Presentation Paper Presentation
Geographic Reach International
Primary Audience Other academic audiences (collaborators, peers etc.)
Results and Impact James Bluett presented his reasearch in a talk entitled: LONG-TERM PERSISTENCE WITH ORAL METHOTREXATE IN PATIENTS WITH EARLY INFLAMMATORY ARTHRITIS

None yet
Year(s) Of Engagement Activity 2006,2009,2014
 
Description Thoracic Society Winter Meeting 2015 (Tim Felton) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Poster presentation: Clinical effectiveness of non-invasive ventilation in patients with Motor Neuron Disease (Freeman D, Jothieswaran A, Mascareno M, Chaudhry N, Bokhari S, Felton TW, Bentley AM. )
Year(s) Of Engagement Activity 2015
 
Description Translational Medicine and Therapeutics Research Showcase 2013 (Edinburgh)(All NWE MRC CPT Fellows) 
Form Of Engagement Activity Scientific meeting (conference/symposium etc.)
Part Of Official Scheme? No
Type Of Presentation Paper Presentation
Geographic Reach National
Primary Audience Other academic audiences (collaborators, peers etc.)
Results and Impact NWE MRC Research Fellows joined with Research Fellows from similar schemes in Glasgow and Edinburgh. Research in the form of presentations and posters was shared between fellows and approx. 60 academics and industry researchers.

An opportunity for Fellows to network and share research experience.
Year(s) Of Engagement Activity 2013
 
Description UK CF Clinical Trials Meeting, Bristol (2015) (Stephen McWilliam) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact This event took place in Bristol. There were probably around 100 people present. I presented 'The PROteKT study' to a group of clinicians and researchers involved in CF clinical care and trial. Promoted wider awareness of the trial and generated interest
Year(s) Of Engagement Activity 2015
 
Description UK Health Tech Conference (2015) (Richard Myles Turner) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Richard Turner gave an oral presentation entitled, 'Developing and implementing genetic tests for personalised medicine' covering implementation of pharmacogenetic tests for personalised medicine, at the UK Health Tech Conference (2015). This led to interesting and productive conversations. This activity provided publicity for both work already undertaken by the Wolfson Centre for Personalised Medicine (University of Liverpool) and for pharmacogenetics implementation projects and initiatives that Liverpool is currently undertaking.
Year(s) Of Engagement Activity 2015
URL http://www.ukhealthtech.com/
 
Description University of Manchester Widening Participation video to encourage school students into taking science degrees (Amy Foulkes) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Type Of Presentation Keynote/Invited Speaker
Geographic Reach National
Primary Audience Schools
Results and Impact http://www.youtube.com/watch?v=g66ad_1pqPE&feature=youtu.be Video viewed 103 times on You tube.

Encouraging school students to think about taking degrees in bioscience.
Year(s) Of Engagement Activity 2012
URL http://www.youtube.com/watch?v=g66ad_1pqPE
 
Description Video about what it's like to be a PhD Student at the University of Manchester (Amy Foulkes) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Type Of Presentation Keynote/Invited Speaker
Geographic Reach National
Primary Audience Undergraduate students
Results and Impact http://www.mhs.manchester.ac.uk/postgraduate/videochangingfacePhD/
Amy foulkes featured in a video entitled the 'changing face of the PhD encouraging students to consider PhD research

Video available on University of Manchester website to be viewed by future generations of phD students.
Year(s) Of Engagement Activity 2012
 
Description Welsh Sixth Form Conference 2014 'Discovering Genomics' (Dan Hawcutt and Vincent Yip) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Public/other audiences
Results and Impact A presentation delivered to sixth form students entitled 'Pharmacogenomics: Personalising Medicine' was delivered to an audience of Sixth From students and the Wales Gene Park sixth form conference. The presentation sparked questions and discussion from the students.

Further invitations to take part in this kind of event.
Year(s) Of Engagement Activity 2014
URL http://www.walesgenepark.cardiff.ac.uk/2014/10/15/sixth-form-conferences-2014/
 
Description Women in Science Edit-a-Thon (Liverpool) 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? Yes
Geographic Reach Regional
Primary Audience Public/other audiences
Results and Impact 21 people attended an edit-a-thon focussed on Women in Science. This began with a training session from three wikimedia volunteers about how to edit the website wikipedia. This was then followed by an editing session lasting approximately 4 hours in which the editing group (made up of University staff, students and members of the public created and/or improved 12 wikipedia pages dedicated to female scientists.

The editing session was then followed by a Key note talk about women in Science from Dame Julia Higgins and a panel discussion Charied by Executive Pro-Vice Chancellor, Prof Fiona Beveridge, featuring three University of Liverpool Professors (Prof Susan Wray, Prof Tara Shears and Prof Jude Robinson) and MRC Clinical Research Fellows (Dr Lauren Walker and Dr Sarah Skeoch). The key note talk was attended by approx. 60 people (a combination of University staff, students and members of the public). Approximately 80 people attended this panel session.

- The creation of 12 wikipedia pages about women in science.
- 21 people trained as Wikipedia editors
- Potential for further wikipedia editing projects (e.g. improving information about drugs and pharmacology on Wikipedia)
Year(s) Of Engagement Activity 2014
URL https://en.wikipedia.org/wiki/Wikipedia:WikiProject_Women_scientists/Editathon_13_May_2014_-_Univers...
 
Description Women in Science Edit-a-Thon (Manchester) 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? Yes
Geographic Reach Regional
Primary Audience Public/other audiences
Results and Impact The Wiki edit-a-thon was held in the Main Library at The University of Manchester providing access to a rich collection of printed and electronic works about women in science. The workshop was attended by 17 individuals working and studying across the University who wanted to make a difference to this important gender agenda. During the workshop participants learnt how to edit, create and improve Wikipedia articles.

The Women in Science Panel Discussion was held in the Manchester Museum at The University of Manchester and attracted over 50 academics, researchers, students, and teachers from both inside and outside the University. The event offered the opportunity to listen to panellists who each spoke openly about their role and their progression at the University, and shared their own experiences as a woman in science. The panellists each offered hints and tips, as well as discussing the challenges they faced. Our panellists were Professor Dame Nancy Rothwell (President and Vice Chancellor of the University, Professor of Physiology), Professor Dame Tina Lavendar (Professor of Midwifery), Professor Dame Nicky Cullum (Professor of Nursing) and Professor Helen Gleeson (Professor of Physics). The panel was facilitated by Professor Chris Griffiths (Professor of Dermatology). An informal networking session followed the discussion.

In response to the editing session participants reported "feeling inspired" and requested "follow-up sessions" the University is now looking to host monthly Edit-a-thon sessions to ensure the editing skills learnt will not be forgotten! An advanced workshop for our 'experienced' Wiki editors is planned for later in the year.
Year(s) Of Engagement Activity 2014
URL https://wikimedia.org.uk/wiki/Women_in_Science_Wikipedia_Edit-a-thon_at_the_University_of_Manchester...